

Edgar Filing: Physicians Realty Trust - Form 10-Q

Physicians Realty Trust

Form 10-Q

May 04, 2018

falsefalse--12-31--12-31Q1Q1201820182018-03-312018-03-3110-Q10-Q00015745400001583994182004287YesNoLarge  
Accelerated FilerNon-accelerated FilerPhysicians Realty TrustPhysicians Realty  
L.P.P1Y10.015000000001814400511819437251814400511819437250.00850.0140.010.01550.0120.0180.00900.01450.01550  
0001574540 2018-01-01 2018-03-31 0001574540 doc:PhysiciansRealtyLPMember 2018-01-01 2018-03-31  
0001574540 2018-04-30 0001574540 2017-12-31 0001574540 2018-03-31 0001574540 2017-01-01 2017-03-31  
0001574540 us-gaap:NoncontrollingInterestMember 2017-12-31 0001574540 us-gaap:NoncontrollingInterestMember  
2018-01-01 2018-03-31 0001574540 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001574540  
us-gaap:RetainedEarningsMember 2018-03-31 0001574540  
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-03-31 0001574540  
us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001574540 us-gaap:ParentMember 2018-01-01  
2018-03-31 0001574540 doc:OperatingPartnershipNoncontrollingInterestMember 2018-01-01 2018-03-31  
0001574540 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2017-12-31 0001574540  
doc:PartiallyOwnedPropertiesNoncontrollingInterestMember 2018-03-31 0001574540 us-gaap:ParentMember  
2017-12-31 0001574540 us-gaap:CommonStockMember 2018-03-31 0001574540  
us-gaap:NoncontrollingInterestMember 2018-03-31 0001574540 us-gaap:AdditionalPaidInCapitalMember  
2018-01-01 2018-03-31 0001574540 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001574540  
doc:PartiallyOwnedPropertiesNoncontrollingInterestMember 2018-01-01 2018-03-31 0001574540  
us-gaap:CommonStockMember 2017-12-31 0001574540  
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-03-31 0001574540  
us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001574540  
doc:OperatingPartnershipNoncontrollingInterestMember 2017-12-31 0001574540  
doc:PartiallyOwnedPropertiesNoncontrollingInterestMember 2017-12-31 0001574540  
us-gaap:RetainedEarningsMember 2017-12-31 0001574540 us-gaap:ParentMember 2018-03-31 0001574540  
doc:OperatingPartnershipNoncontrollingInterestMember 2018-03-31 0001574540 2016-12-31 0001574540  
2017-03-31 0001574540 doc:PhysiciansRealtyLPMember 2017-01-01 2017-03-31 0001574540  
doc:PhysiciansRealtyLPMember 2017-12-31 0001574540 doc:PhysiciansRealtyLPMember 2018-03-31 0001574540  
doc:PhysiciansRealtyLPMember doc:PartiallyOwnedPropertiesNoncontrollingInterestMember 2018-01-01  
2018-03-31 0001574540 doc:PhysiciansRealtyLPMember doc:PartnersCapitalMember 2018-01-01 2018-03-31  
0001574540 doc:PhysiciansRealtyLPMember us-gaap:GeneralPartnerMember 2018-01-01 2018-03-31 0001574540  
doc:PhysiciansRealtyLPMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001574540  
doc:PhysiciansRealtyLPMember doc:PartnersCapitalMember 2018-03-31 0001574540  
doc:PhysiciansRealtyLPMember us-gaap:LimitedPartnerMember 2018-01-01 2018-03-31 0001574540  
doc:PhysiciansRealtyLPMember us-gaap:GeneralPartnerMember 2017-12-31 0001574540  
doc:PhysiciansRealtyLPMember doc:PartiallyOwnedPropertiesNoncontrollingInterestMember 2017-12-31  
0001574540 doc:PhysiciansRealtyLPMember doc:PartnersCapitalMember 2017-12-31 0001574540  
doc:PhysiciansRealtyLPMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001574540  
doc:PhysiciansRealtyLPMember us-gaap:LimitedPartnerMember 2017-12-31 0001574540  
doc:PhysiciansRealtyLPMember us-gaap:LimitedPartnerMember 2018-03-31 0001574540  
doc:PhysiciansRealtyLPMember us-gaap:GeneralPartnerMember 2018-03-31 0001574540  
doc:PhysiciansRealtyLPMember doc:PartiallyOwnedPropertiesNoncontrollingInterestMember 2018-03-31  
0001574540 doc:PhysiciansRealtyLPMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01  
2018-03-31 0001574540 doc:PhysiciansRealtyLPMember 2016-12-31 0001574540 doc:PhysiciansRealtyLPMember  
2017-03-31 0001574540 doc:A2016ATMProgramMember us-gaap:PrivatePlacementMember 2018-01-01 2018-03-31  
0001574540 us-gaap:SubsequentEventMember 2018-04-30 0001574540 doc:A2016ATMProgramMember  
us-gaap:MaximumMember us-gaap:PrivatePlacementMember 2016-08-05 2016-08-05 0001574540 2018-03-23  
2018-03-23 0001574540 2015-03-01 0001574540 doc:MezzanineLoanReceivableMember 2018-03-31 0001574540  
us-gaap:SeriesAPreferredStockMember 2015-02-05 2015-02-05 0001574540  
doc:HealthEastClinicSpecialtyCenterMember 2018-01-09 2018-01-09 0001574540

Edgar Filing: Physicians Realty Trust - Form 10-Q

us-gaap:SeriesAPreferredStockMember 2015-02-05 0001574540 us-gaap:InterestRateSwapMember  
us-gaap:CashFlowHedgingMember 2018-03-31 0001574540 us-gaap:InterestRateSwapMember  
us-gaap:CashFlowHedgingMember 2017-01-01 2017-03-31 0001574540 doc:TermLoanReceivableMember  
2018-03-31 0001574540 doc:RedeemableNoncontrollingInterestBuyoutsMember 2018-03-01 2018-03-01  
0001574540 2015-03-01 2015-03-01 0001574540 doc:HealthEastClinicSpecialtyCenterMember 2018-01-01  
2018-03-31 0001574540 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember  
doc:MichiganandFloridaMember 2018-01-01 2018-03-31 0001574540  
us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember doc:MichiganandFloridaMember  
2017-01-01 2017-03-31 0001574540 doc:LoanInvestmentsMember 2018-01-01 2018-03-31 0001574540  
doc:HazelwoodMedicalcommonsMember 2018-01-09 0001574540  
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2018-01-01 2018-03-31 0001574540  
doc:RedeemableNoncontrollingInterestBuyoutsMember 2018-03-01 0001574540 doc:LoanInvestmentsMember  
2018-02-16 0001574540 doc:HazelwoodMedicalcommonsMember 2018-01-09 2018-01-09 0001574540  
doc:LoanInvestmentsMember 2018-02-16 2018-02-16 0001574540 doc:ScottsdaleArizonaLandMember 2018-02-16  
2018-02-16 0001574540 doc:LeesHillMedicalPlazaMember 2018-01-23 2018-01-23 0001574540  
doc:AcquiredLeaseIntangiblesMember 2018-03-31 0001574540 us-gaap:OtherAssetsMember 2018-03-31  
0001574540 us-gaap:LandAndLandImprovementsMember 2018-03-31 0001574540  
us-gaap:BuildingAndBuildingImprovementsMember 2018-03-31 0001574540 doc:TenantImprovementsMember  
2018-03-31 0001574540 us-gaap:AboveMarketLeasesMember 2018-03-31 0001574540  
us-gaap:LeasesAcquiredInPlaceMember 2018-03-31 0001574540 doc:BelowMarketLeasesMember 2018-03-31  
0001574540 doc:LeaseholdInterestMember 2017-12-31 0001574540 doc:LeaseholdInterestMember 2018-03-31  
0001574540 doc:AboveMarketGroundLeaseMember 2017-12-31 0001574540 us-gaap:AboveMarketLeasesMember  
2017-12-31 0001574540 doc:BelowMarketLeasesMember 2017-12-31 0001574540  
us-gaap:LeasesAcquiredInPlaceMember 2017-12-31 0001574540 doc:AboveMarketGroundLeaseMember  
2018-03-31 0001574540 doc:BelowMarketGroundLeaseMember 2017-12-31 0001574540  
doc:BelowMarketGroundLeaseMember 2018-03-31 0001574540 us-gaap:SalesRevenueServicesNetMember  
us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-03-31 0001574540  
us-gaap:SalesRevenueServicesNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-03-31  
0001574540 us-gaap:LeasesAcquiredInPlaceMember 2018-01-01 2018-03-31 0001574540  
doc:AboveMarketGroundLeaseMember 2017-01-01 2017-03-31 0001574540 doc:BelowMarketLeasesMember  
2017-01-01 2017-03-31 0001574540 doc:LeaseholdInterestMember 2017-01-01 2017-03-31 0001574540  
doc:AboveMarketGroundLeaseMember 2018-01-01 2018-03-31 0001574540 doc:BelowMarketGroundLeaseMember  
2018-01-01 2018-03-31 0001574540 doc:BelowMarketGroundLeaseMember 2017-01-01 2017-03-31 0001574540  
us-gaap:AboveMarketLeasesMember 2017-01-01 2017-03-31 0001574540 us-gaap:AboveMarketLeasesMember  
2018-01-01 2018-03-31 0001574540 doc:BelowMarketLeasesMember 2018-01-01 2018-03-31 0001574540  
us-gaap:LeasesAcquiredInPlaceMember 2017-01-01 2017-03-31 0001574540 doc:LeaseholdInterestMember  
2018-01-01 2018-03-31 0001574540 us-gaap:SeniorNotesMember 2017-03-07 0001574540 us-gaap:SeriesAMember  
us-gaap:SeniorNotesMember 2016-08-11 0001574540 doc:PhysiciansRealtyLPMember  
us-gaap:RevolvingCreditFacilityMember 2018-03-31 0001574540 doc:CreditAgreementAmendmentMember  
2018-01-01 2018-03-31 0001574540 doc:CreditAgreementAmendmentMember doc:TermLoanMember 2016-06-10  
2016-06-10 0001574540 doc:MortgageNotesBearingVariableInterestDue2018Member us-gaap:MortgagesMember  
us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-01-01 2017-03-31  
0001574540 us-gaap:SeriesBMember us-gaap:SeniorNotesMember 2016-08-11 0001574540  
doc:MortgageNotesBearingFixedInterestRateDueIn201720182019202020212022and2032And2022Member  
us-gaap:MortgagesMember us-gaap:MinimumMember 2018-03-31 0001574540 us-gaap:SeriesBMember  
us-gaap:SeniorNotesMember 2016-01-07 0001574540 doc:CreditAgreementAmendmentMember 2016-06-10  
2016-06-10 0001574540 doc:SeriesDMember us-gaap:SeniorNotesMember 2016-01-07 0001574540  
doc:CreditAgreementAmendmentMember 2016-06-10 0001574540 doc:PhysiciansRealtyLPMember  
us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01  
2018-03-31 0001574540 doc:MortgageNotesBearingVariableInterestDue2018Member us-gaap:MortgagesMember  
2017-12-31 0001574540 doc:MortgageNotesBearingVariableInterestDue2018Member us-gaap:MortgagesMember

Edgar Filing: Physicians Realty Trust - Form 10-Q

2018-03-31 0001574540 doc:MortgageNotesBearingVariableInterestDue2018Member us-gaap:MortgagesMember us-gaap:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-01-01 2017-03-31 0001574540 doc:SeriesCMember 2016-01-07 0001574540  
doc:MortgageNotesBearingFixedInterestRateDueIn201720182019202020212022and2032And2022Member us-gaap:MortgagesMember 2017-12-31 0001574540 us-gaap:SeniorNotesMember 2016-08-11 0001574540 us-gaap:InterestRateSwapMember us-gaap:UnsecuredDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-07-07 0001574540  
doc:CreditAgreementAmendmentMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0001574540 us-gaap:SeriesBMember 2016-01-07 0001574540 us-gaap:SeniorNotesMember 2016-01-07 0001574540 doc:SeriesCMember us-gaap:SeniorNotesMember 2016-08-11 0001574540 us-gaap:SeriesAMember 2016-08-11 0001574540  
doc:MortgageNotesBearingFixedInterestRateDueIn201720182019202020212022and2032And2022Member us-gaap:MortgagesMember 2018-03-31 0001574540 us-gaap:RevolvingCreditFacilityMember 2018-03-31 0001574540  
doc:MortgageNotesBearingFixedInterestRateDueIn201720182019202020212022and2032And2022Member us-gaap:MortgagesMember us-gaap:MaximumMember 2017-12-31 0001574540 us-gaap:SeriesAMember 2016-01-07 0001574540 us-gaap:SeniorNotesMember 2017-12-01 2017-12-01 0001574540  
doc:MortgageNotesBearingVariableInterestDue2018Member us-gaap:MortgagesMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0001574540  
doc:CreditAgreementAmendmentMember doc:TermLoanMember 2016-06-10 0001574540 doc:SeriesDMember 2016-01-07 0001574540 doc:TermLoanMember 2018-03-31 0001574540 doc:CreditAgreementAmendmentMember us-gaap:RevolvingCreditFacilityMember us-gaap:MinimumMember 2016-06-09 0001574540 us-gaap:SeriesAMember us-gaap:SeniorNotesMember 2016-01-07 0001574540 doc:SeriesCMember us-gaap:SeniorNotesMember 2016-01-07 0001574540  
doc:MortgageNotesBearingFixedInterestRateDueIn201720182019202020212022and2032And2022Member us-gaap:MortgagesMember us-gaap:MinimumMember 2017-12-31 0001574540  
doc:MortgageNotesBearingFixedInterestRateDueIn201720182019202020212022and2032And2022Member us-gaap:MortgagesMember us-gaap:MaximumMember 2018-03-31 0001574540 doc:TermLoanMember 2016-07-07 0001574540 us-gaap:SeniorNotesMember 2017-03-07 2017-03-07 0001574540  
doc:CreditAgreementAmendmentMember us-gaap:RevolvingCreditFacilityMember us-gaap:MaximumMember 2016-06-10 0001574540 doc:UnsecuredTermLoanDueJune2023Member us-gaap:UnsecuredDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-31 0001574540 us-gaap:LetterOfCreditMember 2018-03-31 0001574540 us-gaap:SeriesBMember 2016-08-11 0001574540  
doc:RevolvingCreditFacilityDueSeptember2020Member us-gaap:RevolvingCreditFacilityMember 2018-03-31 0001574540 us-gaap:MortgagesMember 2017-12-31 0001574540  
doc:UnsecuredNotesBearingFixedInterestDueMarch2027Member us-gaap:SeniorNotesMember 2018-03-31 0001574540 doc:UnsecuredNotesBearingFixedInterestDueMarch2027Member us-gaap:SeniorNotesMember 2017-12-31 0001574540 doc:UnsecuredNotesBearingFixedInterestDueJanuary2028Member us-gaap:SeniorNotesMember 2018-03-31 0001574540 doc:SeniorUnsecuredNotesDueAugust2025to2027Member us-gaap:SeniorNotesMember 2018-03-31 0001574540 doc:UnsecuredTermLoanDueJune2023Member us-gaap:UnsecuredDebtMember 2017-12-31 0001574540  
doc:UnsecuredNotesBearingFixedInterestDueJanuary2023to2031Member us-gaap:SeniorNotesMember 2017-12-31 0001574540 doc:SeniorUnsecuredNotesDueAugust2025to2027Member us-gaap:SeniorNotesMember 2017-12-31 0001574540 doc:MortgageNotesBearingVariableInterestMember us-gaap:MortgagesMember 2017-12-31 0001574540 doc:UnsecuredNotesBearingFixedInterestDueJanuary2023to2031Member us-gaap:SeniorNotesMember 2018-03-31 0001574540 doc:UnsecuredTermLoanDueJune2023Member us-gaap:UnsecuredDebtMember 2018-03-31 0001574540 us-gaap:MortgagesMember 2018-03-31 0001574540  
doc:RevolvingCreditFacilityDueSeptember2020Member us-gaap:RevolvingCreditFacilityMember 2017-12-31 0001574540 doc:UnsecuredNotesBearingFixedInterestDueJanuary2028Member us-gaap:SeniorNotesMember 2017-12-31 0001574540 doc:MortgageNotesBearingVariableInterestMember us-gaap:MortgagesMember 2018-03-31 0001574540 doc:CreditratingbelowBBBorBAA3Member doc:BaseRateLoansMember doc:TermLoanMember

Edgar Filing: Physicians Realty Trust - Form 10-Q

us-gaap:BaseRateMember 2018-01-01 2018-03-31 0001574540 doc:CreditratingatleastBBBplusorBAA1Member  
doc:BaseRateLoansMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2018-01-01  
2018-03-31 0001574540 doc:CreditratingatleastBBBorBAA3Member doc:BaseRateLoansMember  
us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2018-01-01 2018-03-31 0001574540  
doc:CreditratingbelowBBBorBAA3Member doc:BaseRateLoansMember us-gaap:RevolvingCreditFacilityMember  
us-gaap:BaseRateMember 2018-01-01 2018-03-31 0001574540 doc:CreditratingatleastAorA3Member  
doc:BaseRateLoansMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2018-01-01  
2018-03-31 0001574540 doc:CreditratingatleastBBBorBAA2Member doc:BaseRateLoansMember  
us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2018-01-01 2018-03-31 0001574540  
doc:CreditratingatleastBBBorBAA3Member doc:BaseRateLoansMember doc:TermLoanMember  
us-gaap:BaseRateMember 2018-01-01 2018-03-31 0001574540 doc:CreditratingatleastAorA3Member  
doc:BaseRateLoansMember doc:TermLoanMember us-gaap:BaseRateMember 2018-01-01 2018-03-31 0001574540  
doc:CreditratingatleastBBBorBAA2Member doc:BaseRateLoansMember doc:TermLoanMember  
us-gaap:BaseRateMember 2018-01-01 2018-03-31 0001574540 doc:CreditratingatleastBBBplusorBAA1Member  
doc:BaseRateLoansMember doc:TermLoanMember us-gaap:BaseRateMember 2018-01-01 2018-03-31 0001574540  
doc:CreditratingatleastAorA3Member doc:AdjustedLIBORRateTermLoansAndLetterOfCreditMember  
us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0001574540  
doc:CreditratingatleastAorA3Member doc:AdjustedLIBORRateRevolverLoansAndLetterOfCreditMember  
us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0001574540  
doc:CreditratingatleastBBBorBAA2Member doc:AdjustedLIBORRateRevolverLoansAndLetterOfCreditMember  
us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0001574540  
doc:CreditratingbelowBBBorBAA3Member doc:AdjustedLIBORRateTermLoansAndLetterOfCreditMember  
us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0001574540  
doc:CreditratingatleastBBBplusorBAA1Member doc:AdjustedLIBORRateTermLoansAndLetterOfCreditMember  
us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0001574540  
doc:CreditratingatleastBBBorBAA3Member doc:AdjustedLIBORRateRevolverLoansAndLetterOfCreditMember  
us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0001574540  
doc:CreditratingatleastBBBplusorBAA1Member doc:AdjustedLIBORRateRevolverLoansAndLetterOfCreditMember  
us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0001574540  
doc:CreditratingatleastBBBorBAA3Member doc:AdjustedLIBORRateTermLoansAndLetterOfCreditMember  
us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0001574540  
doc:CreditratingatleastBBBorBAA2Member doc:AdjustedLIBORRateTermLoansAndLetterOfCreditMember  
us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0001574540  
doc:CreditratingbelowBBBorBAA3Member doc:AdjustedLIBORRateRevolverLoansAndLetterOfCreditMember  
us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0001574540  
doc:UnsecuredNotesBearingFixedInterestDueJanuary2023to2031Member us-gaap:SeniorNotesMember  
us-gaap:MaximumMember 2018-03-31 0001574540 doc:SeniorUnsecuredNotesDueAugust2025to2027Member  
us-gaap:SeniorNotesMember us-gaap:MaximumMember 2018-03-31 0001574540  
doc:SeniorUnsecuredNotesDueAugust2025to2027Member us-gaap:SeniorNotesMember us-gaap:MinimumMember  
2018-03-31 0001574540 doc:RevolvingCreditFacilityDueSeptember2020Member  
us-gaap:RevolvingCreditFacilityMember 2018-01-01 2018-03-31 0001574540  
doc:UnsecuredNotesBearingFixedInterestDueJanuary2023to2031Member us-gaap:SeniorNotesMember  
us-gaap:MinimumMember 2018-03-31 0001574540 doc:UnsecuredTermLoanDueJune2023Member  
us-gaap:UnsecuredDebtMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31  
0001574540 us-gaap:RevolvingCreditFacilityMember 2018-01-01 2018-03-31 0001574540  
us-gaap:InterestRateSwapMember us-gaap:CarryingReportedAmountFairValueDisclosureMember  
us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001574540 us-gaap:InterestRateSwapMember  
us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember  
2018-03-31 0001574540 us-gaap:InterestRateSwapMember us-gaap:UnsecuredDebtMember  
us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-31 0001574540  
us-gaap:RestrictedStockUnitsRSUMember doc:EquityIncentivePlan2013PlanMember 2018-03-31 0001574540

Edgar Filing: Physicians Realty Trust - Form 10-Q

us-gaap:RestrictedStockUnitsRSUMember doc:EquityIncentivePlan2013PlanMember 2018-03-01 2018-03-31 0001574540 us-gaap:RestrictedStockMember doc:EquityIncentivePlan2013PlanMember 2018-01-01 2018-03-31 0001574540 doc:MarketBasedRestrictedStockUnitsRSUsMember doc:EquityIncentivePlan2013PlanMember doc:OfficersandCertainEmployeesMember 2018-03-01 2018-03-31 0001574540 doc:ExecutiveAwardsRestrictedStockUnitsRSUsMember doc:EquityIncentivePlan2013PlanMember 2018-01-01 2018-03-31 0001574540 us-gaap:RestrictedStockMember doc:EquityIncentivePlan2013PlanMember doc:OfficersandCertainEmployeesMember 2018-01-01 2018-03-31 0001574540 doc:PerformanceBasedRestrictedStockUnitsRSUsMember doc:EquityIncentivePlan2013PlanMember 2018-03-01 2018-03-31 0001574540 doc:ExecutiveAwardsRestrictedStockUnitsRSUsMember doc:EquityIncentivePlan2013PlanMember 2018-03-31 0001574540 us-gaap:RestrictedStockUnitsRSUMember doc:EquityIncentivePlan2013PlanMember doc:TrusteesMember 2018-03-01 2018-03-31 0001574540 us-gaap:RestrictedStockMember doc:EquityIncentivePlan2013PlanMember 2017-01-01 2017-03-31 0001574540 us-gaap:RestrictedStockUnitsRSUMember doc:EquityIncentivePlan2013PlanMember doc:OfficersandCertainEmployeesMember 2018-03-01 2018-03-31 0001574540 doc:PerformanceBasedRestrictedStockUnitsRSUsMember doc:EquityIncentivePlan2013PlanMember doc:TrusteesMember 2018-03-01 2018-03-31 0001574540 us-gaap:RestrictedStockMember doc:EquityIncentivePlan2013PlanMember 2018-03-31 0001574540 us-gaap:RestrictedStockUnitsRSUMember doc:EquityIncentivePlan2013PlanMember doc:EquityIncentivePlan2013PlanMember 2018-01-01 2018-03-31 0001574540 us-gaap:RestrictedStockMember doc:EquityIncentivePlan2013PlanMember 2014-08-07 2014-08-07 0001574540 doc:PerformanceBasedRestrictedStockUnitsRSUsMember doc:EquityIncentivePlan2013PlanMember doc:OfficersandCertainEmployeesMember 2018-03-01 2018-03-31 0001574540 us-gaap:RestrictedStockUnitsRSUMember doc:EquityIncentivePlan2013PlanMember 2017-01-01 2017-03-31 0001574540 us-gaap:RestrictedStockMember doc:EquityIncentivePlan2013PlanMember 2014-08-07 0001574540 us-gaap:RestrictedStockMember doc:EquityIncentivePlan2013PlanMember 2013-07-24 0001574540 doc:ExecutiveAwardsRestrictedStockUnitsRSUsMember doc:EquityIncentivePlan2013PlanMember 2017-12-31 0001574540 doc:TrusteeAwardsRestrictedStockUnitsRSUsMember doc:EquityIncentivePlan2013PlanMember 2018-01-01 2018-03-31 0001574540 doc:TrusteeAwardsRestrictedStockUnitsRSUsMember doc:EquityIncentivePlan2013PlanMember 2017-12-31 0001574540 doc:TrusteeAwardsRestrictedStockUnitsRSUsMember doc:EquityIncentivePlan2013PlanMember 2018-03-31 0001574540 us-gaap:RestrictedStockMember doc:EquityIncentivePlan2013PlanMember 2017-12-31 0001574540 us-gaap:RestrictedStockUnitsRSUMember doc:EquityIncentivePlan2013PlanMember doc:TrusteesMember 2018-01-01 2018-03-31 0001574540 us-gaap:RestrictedStockUnitsRSUMember doc:EquityIncentivePlan2013PlanMember doc:OfficersandCertainEmployeesMember 2018-01-01 2018-03-31 0001574540 us-gaap:FairValueMeasurementsNonrecurringMember 2018-03-31 0001574540 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0001574540 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0001574540 us-gaap:InterestRateSwapMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001574540 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001574540 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001574540 us-gaap:InterestRateSwapMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0001574540 us-gaap:OperatingExpenseMember doc:ParkingAirAndGroundLeasesMember 2017-01-01 2017-03-31 0001574540 us-gaap:OperatingExpenseMember doc:ParkingAirAndGroundLeasesMember 2018-01-01 2018-03-31 0001574540 us-gaap:SalesRevenueServicesNetMember us-gaap:GeographicConcentrationRiskMember str:TX 2018-01-01 2018-03-31 0001574540 us-gaap:SalesRevenueServicesNetMember us-gaap:GeographicConcentrationRiskMember doc:AllotherstatesMember 2018-01-01 2018-03-31 0001574540 us-gaap:SalesRevenueServicesNetMember us-gaap:GeographicConcentrationRiskMember str:GA 2018-01-01 2018-03-31 0001574540 us-gaap:SalesRevenueServicesNetMember us-gaap:GeographicConcentrationRiskMember str:IN 2018-01-01 2018-03-31 0001574540 us-gaap:SalesRevenueServicesNetMember

Edgar Filing: Physicians Realty Trust - Form 10-Q

us-gaap:GeographicConcentrationRiskMember stpr:MN 2018-01-01 2018-03-31 0001574540  
us-gaap:SalesRevenueServicesNetMember us-gaap:GeographicConcentrationRiskMember stpr:NE 2018-01-01  
2018-03-31 0001574540 us-gaap:SalesRevenueServicesNetMember 2018-01-01 2018-03-31 0001574540  
us-gaap:SalesRevenueServicesNetMember us-gaap:CustomerConcentrationRiskMember  
doc:TopfivetenantrelationshipsMember 2018-01-01 2018-03-31 0001574540  
us-gaap:SalesRevenueServicesNetMember us-gaap:CustomerConcentrationRiskMember doc:CHIPortfolioMember  
2018-01-01 2018-03-31 0001574540 us-gaap:SalesRevenueServicesNetMember  
us-gaap:CustomerConcentrationRiskMember doc:CHINebraskaMember 2018-01-01 2018-03-31 0001574540  
us-gaap:SalesRevenueServicesNetMember us-gaap:CustomerConcentrationRiskMember  
doc:NorthsideHospitalGAMember 2018-01-01 2018-03-31 0001574540 us-gaap:SalesRevenueServicesNetMember  
us-gaap:CustomerConcentrationRiskMember doc:BaylorScottandWhiteHealthMember 2018-01-01 2018-03-31  
0001574540 us-gaap:SalesRevenueServicesNetMember us-gaap:CustomerConcentrationRiskMember  
doc:USOncologyMember 2018-01-01 2018-03-31 0001574540 us-gaap:SalesRevenueServicesNetMember  
us-gaap:CustomerConcentrationRiskMember doc:RemainingPortfolioMember 2018-01-01 2018-03-31 0001574540  
us-gaap:SalesRevenueServicesNetMember us-gaap:CustomerConcentrationRiskMember  
doc:CHIKentuckyOneHealthMember 2018-01-01 2018-03-31 0001574540 us-gaap:RestrictedStockMember  
2017-01-01 2017-03-31 0001574540 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0001574540  
us-gaap:RestrictedStockMember 2018-01-01 2018-03-31 0001574540 us-gaap:RestrictedStockUnitsRSUMember  
2018-01-01 2018-03-31 0001574540 doc:PhysiciansRealtyLPMember us-gaap:RestrictedStockUnitsRSUMember  
2018-01-01 2018-03-31 0001574540 doc:PhysiciansRealtyLPMember us-gaap:RestrictedStockUnitsRSUMember  
2017-01-01 2017-03-31 0001574540 doc:PhysiciansRealtyLPMember us-gaap:RestrictedStockMember 2017-01-01  
2017-03-31 0001574540 doc:PhysiciansRealtyLPMember us-gaap:RestrictedStockMember 2018-01-01 2018-03-31  
0001574540 doc:MedicalOfficeFacilityKingsportTennesseeMember us-gaap:SubsequentEventMember 2018-04-03  
2018-04-03 doc:instruments doc:properties doc:states iso4217:USD xbrli:shares doc:portfolio xbrli:pure  
doc:disposition\_group doc:buildings doc:land xbrli:shares doc:segment iso4217:USD doc:mezzanine\_loan  
doc:healthcareproperty utreg:Rate

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2018

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: 001-36007 (Physicians Realty Trust)

Commission file number: 333-205034-01 (Physicians Realty L.P.)

**PHYSICIANS REALTY TRUST  
PHYSICIANS REALTY L.P.**

## Edgar Filing: Physicians Realty Trust - Form 10-Q

(Exact Name of Registrant as Specified in its Charter)

**Maryland (Physicians Realty Trust)**      **46-2519850**  
**Delaware (Physicians Realty L.P.)**      **80-0941870**  
(State of Organization)                      (IRS Employer Identification No.)

**309 N. Water Street,**  
**Suite 500**                                      **53202**  
**Milwaukee, Wisconsin**                  (Zip Code)  
(Address of Principal Executive Offices)

**(414) 367-5600**  
(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Physicians Realty Trust    Yes  No       Physicians Realty L.P.    Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Physicians Realty Trust    Yes  No       Physicians Realty L.P.    Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Physicians Realty Trust    Large accelerated filer     Accelerated filer     Non-accelerated filer  (Do not check if a smaller reporting company)    Smaller reporting company     Emerging growth company

Physicians Realty L.P.    Large accelerated filer     Accelerated filer     Non-accelerated filer  (Do not check if a smaller reporting company)    Smaller reporting company     Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Physicians Realty Trust     Physicians Realty L.P.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Physicians Realty Trust    Yes  No       Physicians Realty L.P.    Yes  No

The number of Physicians Realty Trust's common shares outstanding as of April 30, 2018 was 182,004,287.

---

## EXPLANATORY NOTE

This Quarterly Report on Form 10-Q combines the Quarterly Reports on Form 10-Q for the quarter ended March 31, 2018 of Physicians Realty Trust (the “Trust”), a Maryland real estate investment trust, and Physicians Realty L.P. (the “Operating Partnership”), a Delaware limited partnership. Unless otherwise indicated or unless the context requires otherwise, all references in this report to “we,” “us,” “our,” and the “Company,” refer to the Trust, together with its consolidated subsidiaries, including the Operating Partnership. References to the “Operating Partnership” mean collectively the Operating Partnership, together with its consolidated subsidiaries. In this report, all references to “common shares” refer to the common shares of the Trust and references to “our shareholders” refer to shareholders of the common shares of the Trust, the term “OP Units” refers to partnership interests of the Operating Partnership and the term “Series A Preferred Units” refers to Series A Participating Redeemable Preferred Units of the Operating Partnership.

The Trust is a self-managed real estate investment trust (“REIT”) formed primarily to acquire, selectively develop, own, and manage healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems. The Trust’s operations are conducted through the Operating Partnership and wholly-owned and majority-owned subsidiaries of the Operating Partnership. The Trust, as the general partner of the Operating Partnership, controls the Operating Partnership and consolidates the assets, liabilities, and results of operations of the Operating Partnership.

The Trust conducts substantially all of its operations through the Operating Partnership. As of March 31, 2018, the Trust held a 97.1% interest in the Operating Partnership and owns no Series A Preferred Units. Apart from this ownership interest, the Trust has no independent operations.

Noncontrolling interests in the Operating Partnership, shareholders’ equity of the Trust and partners’ capital of the Operating Partnership are the primary areas of difference between the consolidated financial statements of the Trust and those of the Operating Partnership. OP Units not owned by the Trust are accounted for as limited partners’ capital in the Operating Partnership’s consolidated financial statements and as noncontrolling interests in the Trust’s consolidated financial statements. The differences between the Trust’s shareholders’ equity and the Operating Partnership’s partners’ capital are due to the differences in the equity issued by the Trust and the Operating Partnership, respectively.

The Company believes combining the Quarterly Reports of the Trust and the Operating Partnership, including the notes to the consolidated financial statements, into this single report results in the following benefits:

- a combined report enhances investors’ understanding of the Trust and the Operating Partnership by enabling investors to view the business as a whole in the same manner as management views and operates the business;
- a combined report eliminates duplicative disclosure and provides a more streamlined and readable presentation, as a substantial portion of the Company’s disclosure applies to both the Trust and the Operating Partnership; and
- a combined report creates time and cost efficiencies through the preparation of one combined report instead of two separate reports.

To help investors understand the significant differences between the Trust and the Operating Partnership, this report presents the following separate sections for each of the Trust and the Operating Partnership:

- the consolidated financial statements in Part I, Item 1 of this report;
- certain accompanying notes to the consolidated financial statements, including Note 3 (Acquisitions and Dispositions) and Note 14 (Earnings Per Share and Earnings Per Unit);
- controls and procedures in Part I, Item 4 of this report; and
- the certifications of the Chief Executive Officer and the Chief Financial Officer included as Exhibits 31 and 32 to this report.





Table of Contents**PHYSICIANS REALTY TRUST AND PHYSICIANS REALTY L.P.****Quarterly Report on Form 10-Q  
for the Quarter Ended March 31, 2018****Table of Contents**

	<b>Page Number</b>
<b><u>Part I Financial Information</u></b>	
<b><u>Item 1 Financial Statements (Unaudited)</u></b>	
<b>Financial Statements of Physicians Realty Trust</b>	
<u>Consolidated Balance Sheets as of March 31, 2018 and December 31, 2017</u>	<u>3</u>
<u>Consolidated Statements of Income for the Three Months Ended March 31, 2018 and 2017</u>	<u>4</u>
<u>Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2018 and 2017</u>	<u>5</u>
<u>Consolidated Statement of Equity for the Three Months Ended March 31, 2018</u>	<u>6</u>
<u>Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2018 and 2017</u>	<u>7</u>
<b>Financial Statements of Physicians Realty L.P.</b>	
<u>Consolidated Balance Sheets as of March 31, 2018 and December 31, 2017</u>	<u>8</u>
<u>Consolidated Statements of Income for the Three Months Ended March 31, 2018 and 2017</u>	<u>9</u>
<u>Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2018 and 2017</u>	<u>10</u>
<u>Consolidated Statement of Changes in Capital for the Three Months Ended March 31, 2018</u>	<u>11</u>
<u>Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2018 and 2017</u>	<u>12</u>
<b>Notes for Physicians Realty Trust and Physicians Realty L.P.</b>	
<u>Notes to Consolidated Financial Statements</u>	<u>13</u>
<b><u>Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b>	<b><u>35</u></b>
<b><u>Item 3 Quantitative and Qualitative Disclosures About Market Risk</u></b>	<b><u>50</u></b>
<b><u>Item 4 Controls and Procedures</u></b>	<b><u>51</u></b>
<b><u>Part II Other Information</u></b>	
<b><u>Item 1 Legal Proceedings</u></b>	<b><u>52</u></b>
<b><u>Item 1A Risk Factors</u></b>	<b><u>52</u></b>
<b><u>Item 2 Unregistered Sales of Equity Securities and Use of Proceeds</u></b>	<b><u>53</u></b>
<b><u>Item 6 Exhibits</u></b>	<b><u>55</u></b>
<b><u>SIGNATURES</u></b>	<b><u>56</u></b>

Table of Contents

**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains forward-looking statements made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts may be forward-looking statements within the meaning of the federal securities laws. In particular, statements pertaining to our capital resources, property performance and results of operations contain forward-looking statements. Likewise, all of our statements regarding anticipated growth in our funds from operations and anticipated market conditions, demographics and results of operations are forward-looking statements. You can identify forward-looking statements by the use of forward-looking terminology such as “believe,” “expect,” “outlook,” “continue,” “project,” “may,” “will,” “should,” “approximately,” “intend,” “plan,” “pro forma,” “estimate” or “anticipate” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans, expectations or intentions.

These forward-looking statements reflect the views of our management regarding current expectations and projections about future events and are based on currently available information. These forward-looking statements are not guarantees of future performance and involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

- general economic conditions;
- adverse economic or real estate developments, either nationally or in the markets where our properties are located;
- our failure to generate sufficient cash flows to service our outstanding indebtedness, or our ability to pay down or refinance our indebtedness;
- fluctuations in interest rates and increased operating costs;
- the availability, terms and deployment of debt and equity capital, including our unsecured revolving credit facility;
- our ability to make distributions on our common shares;
- general volatility of the market price of our common shares;
- our increased vulnerability economically due to the concentration of our investments in healthcare properties;
- our geographic concentration in Texas causes us to be particularly exposed to downturns in the Texas economy or other changes in Texas market conditions;
- changes in our business or strategy;
- our dependence upon key personnel whose continued service is not guaranteed;
- our ability to identify, hire and retain highly qualified personnel in the future;

- the degree and nature of our competition;
- changes in governmental regulations, tax rates, and similar matters;
- defaults on or non-renewal of leases by tenants;
- decreased rental rates or increased vacancy rates;
- difficulties in identifying healthcare properties to acquire and completing acquisitions;
- competition for investment opportunities;

Table of Contents

any adverse effects to the business, financial position or results of Catholic Health Initiatives' ("CHI"), or one or more of the CHI-affiliated tenants, that impact the ability of CHI-affiliated tenants to pay us rent;

the impact of our investments in joint ventures;

the financial condition and liquidity of, or disputes with, any joint venture and development partners with whom we may make co-investments in the future;

cybersecurity incidents could disrupt our business and result in the compromise of confidential information;

our ability to operate as a public company;

changes in accounting principles generally accepted in the United States (GAAP);

- lack of or insufficient amounts of insurance;

other factors affecting the real estate industry generally;

our failure to maintain our qualification as a REIT for U.S. federal income tax purposes;

limitations imposed on our business and our ability to satisfy complex rules in order for us to qualify as a REIT for U.S. federal income tax purposes;

changes in governmental regulations or interpretations thereof, such as real estate and zoning laws and increases in real property tax rates and taxation of REITs; and

factors that may materially adversely affect us, or the per share trading price of our common shares, including:

higher market interest rates;

the number of our common shares available for future issuance or sale;

our issuance of equity securities or the perception that such issuance might occur;

future debt;

failure of securities analysts to publish research or reports about us or our industry; and

securities analysts' downgrade of our common shares or the healthcare-related real estate sector.

While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this report, except as required by applicable law. You should not place undue reliance on any forward-looking statements that are based on information currently available to us or the third parties making the forward-looking statements. For a further discussion of these and other factors that could impact our future results, performance or transactions, see Part II, Item 1A (Risk Factors) of this report and, Part I, Item 1A (Risk Factors) of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (the "2017 Annual Report").

Table of Contents**PART I. Financial Information****Item 1. Financial Statements****Physicians Realty Trust****Consolidated Balance Sheets***(In thousands, except share and per share data)*

	March 31, 2018 (unaudited)	December 31, 2017
<b><u>ASSETS</u></b>		
Investment properties:		
Land and improvements	\$214,476	\$217,695
Building and improvements	3,570,056	3,568,858
Tenant improvements	19,121	23,056
Acquired lease intangibles	459,836	458,713
	4,263,489	4,268,322
Accumulated depreciation	(318,393 )	(300,458 )
Net real estate property	3,945,096	3,967,864
Real estate held for sale	93,289	—
Real estate loans receivable	71,529	76,195
Investments in unconsolidated entities	1,331	1,329
Net real estate investments	4,111,245	4,045,388
Cash and cash equivalents	6,550	2,727
Tenant receivables, net	4,293	9,966
Other assets	134,919	106,302
Total assets	\$4,257,007	\$4,164,383
<b><u>LIABILITIES AND EQUITY</u></b>		
Liabilities:		
Credit facility	\$466,828	\$324,394
Notes payable	966,387	966,603
Mortgage debt	154,373	186,471
Accounts payable	2,562	11,023
Dividends and distributions payable	43,388	43,804
Accrued expenses and other liabilities	56,706	56,405
Acquired lease intangibles, net	15,767	15,702
Total liabilities	1,706,011	1,604,402
Redeemable noncontrolling interest - Series A Preferred Units (2018) and partially owned properties	23,736	12,347
Equity:		
Common shares, \$0.01 par value, 500,000,000 common shares authorized, 181,943,725 and 181,440,051 common shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	1,819	1,814
Additional paid-in capital	2,778,616	2,772,823
Accumulated deficit	(345,571 )	(315,417 )
Accumulated other comprehensive income	18,250	13,952
Total shareholders' equity	2,453,114	2,473,172
Noncontrolling interests:		
Operating Partnership	73,527	73,844

Edgar Filing: Physicians Realty Trust - Form 10-Q

Partially owned properties	619	618
Total noncontrolling interests	74,146	74,462
Total equity	2,527,260	2,547,634
Total liabilities and equity	\$4,257,007	\$4,164,383

The accompanying notes are an integral part of these consolidated financial statements.

3

---

Table of Contents**Physicians Realty Trust****Consolidated Statements of Income***(In thousands, except share and per share data) (Unaudited)*

	Three Months Ended March 31,	
	2018	2017
<b>Revenues:</b>		
Rental revenues	\$78,887	\$ 59,092
Expense recoveries	24,308	16,354
Interest income on real estate loans and other	2,028	1,220
Total revenues	105,223	76,666
<b>Expenses:</b>		
Interest expense	16,494	9,815
General and administrative	8,459	4,736
Operating expenses	30,459	22,089
Depreciation and amortization	38,576	27,933
Acquisition expenses	—	5,405
Total expenses	93,988	69,978
<b>Income before equity in income of unconsolidated entities and gain on sale of investment properties:</b>	11,235	6,688
Equity in income of unconsolidated entities	28	28
Gain on sale of investment properties	69	—
Net income	11,332	6,716
Net income attributable to noncontrolling interests:		
Operating Partnership	(313 )	(147 )
Partially owned properties (1)	(111 )	(167 )
Net income attributable to controlling interests	10,908	6,402
Preferred distributions	(487 )	(211 )
<b>Net income attributable to common shareholders:</b>	\$10,421	\$ 6,191
Net income per share:		
Basic	\$0.06	\$ 0.04
Diluted	\$0.06	\$ 0.04
Weighted average common shares:		
Basic	181,809,570	188,986,629
Diluted	187,317,243	192,605,930
Dividends and distributions declared per common share and OP Unit	\$0.230	\$ 0.225

(1) An adjustment of \$0.1 million was required for net income attributable to redeemable noncontrolling interests for the three months ended March 31, 2018 and March 31, 2017.

The accompanying notes are an integral part of these consolidated financial statements.



Table of Contents

**Physicians Realty Trust**  
**Consolidated Statements of Comprehensive Income**  
*(In thousands) (Unaudited)*

	Three Months Ended	
	March 31,	
	2018	2017
Net income	\$11,332	\$6,716
Other comprehensive income:		
Change in fair value of interest rate swap agreements	4,298	825
Total other comprehensive income	4,298	825
Comprehensive income	15,630	7,541
Comprehensive income attributable to noncontrolling interests - Operating Partnership	(438 )	(201 )
Comprehensive income attributable to noncontrolling interests - partially owned properties	(111 )	(167 )
Comprehensive income attributable to common shareholders	\$15,081	\$7,173

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

**Physicians Realty Trust**  
**Consolidated Statement of Equity**  
*(In thousands) (Unaudited)*

	Par Value	Additional Paid in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total Shareholders' Equity	Operating Partnership Noncontrolling Interest	Partially Owned Properties Noncontrolling Interest	Total Noncontrolling Interests	Total Equity
Balance at January 1, 2018	\$ 1,814	\$ 2,772,823	\$ (315,417 )	\$ 13,952	\$ 2,473,172	\$ 73,844	\$ 618	\$ 74,462	\$ 2,547,634
Net proceeds from sale of common shares	3	5,313	—	—	5,316	—	—	—	5,316
Restricted share award grants, net	2	872	59	—	933	—	—	—	933
Conversion of OP Units	—	126	—	—	126	(126 )	—	(126 )	—
Dividends/distributions declared	—	—	(41,910 )	—	(41,910 )	(1,216 )	—	(1,216 )	(43,126 )
Preferred distributions	—	—	(487 )	—	(487 )	—	—	—	(487 )
Distributions	—	—	—	—	—	—	(43 )	(43 )	(43 )
Change in market value of Redeemable Noncontrolling Interest in Operating Partnership	—	194	1,276	—	1,470	—	—	—	1,470
Change in fair value of interest rate swap agreements	—	—	—	4,298	4,298	—	—	—	4,298
Net income	—	—	10,908	—	10,908	313	44	357	11,265
Adjustment for Noncontrolling Interests ownership in Operating Partnership	—	(712 )	—	—	(712 )	712	—	712	—
Balance at March 31, 2018	\$ 1,819	\$ 2,778,616	\$ (345,571 )	\$ 18,250	\$ 2,453,114	\$ 73,527	\$ 619	\$ 74,146	\$ 2,527,260

The accompanying notes are an integral part of this consolidated financial statements.

Table of Contents

**Physicians Realty Trust**  
**Consolidated Statements of Cash Flows**  
*(In thousands) (Unaudited)*

	<b>Three Months Ended March 31,</b>	
	<b>2018</b>	<b>2017</b>
<b>Cash Flows from Operating Activities:</b>		
Net income	\$11,332	\$6,716
Adjustments to reconcile net income to net cash provided by operating activities		
Depreciation and amortization	38,576	27,933
Amortization of deferred financing costs	618	549
Amortization of lease inducements and above/below-market lease intangibles	1,190	1,307
Straight-line rental revenue/expense	(6,450 )	(4,508 )
Amortization of discount on unsecured senior notes	142	20
Amortization of above market assumed debt	(16 )	(59 )
Gain on sale of investment properties	(69 )	—
Equity in income of unconsolidated entities	(28 )	(28 )
Distributions from unconsolidated entities	26	55
Change in fair value of derivative	2	165
Provision for bad debts	(141 )	(127 )
Non-cash share compensation	2,605	1,490
Net change in fair value of contingent consideration	—	(70 )
Change in operating assets and liabilities:		
Tenant receivables	5,437	2,703
Other assets	(222 )	(287 )
Accounts payable	(8,461 )	(1,297 )
Accrued expenses and other liabilities	(3,651 )	(676 )
<b>Net cash provided by operating activities</b>	<b>40,890</b>	<b>33,886</b>
<b>Cash Flows from Investing Activities:</b>		
Proceeds on sales of investment properties	2,440	—
Acquisition of investment properties, net	(84,202 )	(174,737 )
Escrowed cash - acquisition deposits / earnest deposits	(2,720 )	1,375
Capital expenditures on existing investment properties	(5,608 )	(3,434 )
Issuance of real estate loans receivable	(2,000 )	(2,279 )
Repayment of real estate loan receivable	6,717	1,507
Issuance of note receivable	(20,385 )	—
Repayment of note receivable	—	16,423
Leasing commissions	(664 )	(552 )
Lease inducements	—	(2,050 )
<b>Net cash used in investing activities</b>	<b>(106,422)</b>	<b>(163,747 )</b>
<b>Cash Flows from Financing Activities:</b>		
Net proceeds from sale of common shares	5,316	301,572
Proceeds from credit facility borrowings	166,000	128,000
Payment on credit facility borrowings	(24,000 )	(529,000 )
Proceeds from issuance of senior unsecured notes	—	396,108
Principal payments on mortgage debt	(32,157 )	(5,823 )
Debt issuance costs	(412 )	(651 )
Dividends paid - shareholders	(42,251 )	(30,945 )
Distributions to noncontrolling interest - Operating Partnership	(1,232 )	(703 )
Preferred distributions paid - OP Unit holder	(81 )	(480 )

## Edgar Filing: Physicians Realty Trust - Form 10-Q

Contributions from noncontrolling interest	—	47
Distributions to noncontrolling interest - partially owned properties	(127 )	(154 )
Payments of employee taxes for withheld stock based compensation shares	(1,701 )	(2,431 )
Purchase of Series A Preferred Units	—	(19,961 )
Purchase of OP Units	—	(3,725 )
<b>Net cash provided by financing activities</b>	<b>69,355</b>	<b>231,854</b>
Net increase in cash and cash equivalents	3,823	101,993
Cash and cash equivalents, beginning of period	2,727	15,491
<b>Cash and cash equivalents, end of period</b>	<b>\$6,550</b>	<b>\$117,484</b>
Supplemental disclosure of cash flow information - interest paid during the period	\$19,230	\$10,764
Supplemental disclosure of noncash activity - change in fair value of interest rate swap agreements	\$4,298	\$825
Supplemental disclosure of noncash activity - assumed debt	\$—	\$26,379
Supplemental disclosure of noncash activity - issuance of OP Units and Series A Preferred Units in connection with acquisitions	\$22,651	\$44,978

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents**Physicians Realty L.P.****Consolidated Balance Sheets***(In thousands, except unit and per unit data)*

	March 31, 2018 (unaudited)	December 31, 2017
<b><u>ASSETS</u></b>		
Investment properties:		
Land and improvements	\$214,476	\$217,695
Building and improvements	3,570,056	3,568,858
Tenant improvements	19,121	23,056
Acquired lease intangibles	459,836	458,713
	4,263,489	4,268,322
Accumulated depreciation	(318,393)	(300,458)
Net real estate property	3,945,096	3,967,864
Real estate held for sale	93,289	—
Real estate loans receivable	71,529	76,195
Investments in unconsolidated entities	1,331	1,329
Net real estate investments	4,111,245	4,045,388
Cash and cash equivalents	6,550	2,727
Tenant receivables, net	4,293	9,966
Other assets	134,919	106,302
Total assets	\$4,257,007	\$4,164,383
<b><u>LIABILITIES AND CAPITAL</u></b>		
Liabilities:		
Credit facility	\$466,828	\$324,394
Notes payable	966,387	966,603
Mortgage debt	154,373	186,471
Accounts payable	2,562	11,023
Dividends and distributions payable	43,388	43,804
Accrued expenses and other liabilities	56,706	56,405
Acquired lease intangibles, net	15,767	15,702
Total liabilities	1,706,011	1,604,402
Redeemable noncontrolling interest - Series A Preferred Units (2018) and partially owned properties	23,736	12,347
Capital:		
Partners' capital:		
General partners' capital, 181,943,725 and 181,440,051 units issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	2,434,864	2,459,220
Limited partners' capital, 5,464,217 and 5,364,632 units issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	73,527	73,844
Accumulated other comprehensive income	18,250	13,952
Total partners' capital	2,526,641	2,547,016
Noncontrolling interest - partially owned properties	619	618
Total capital	2,527,260	2,547,634
Total liabilities and capital	\$4,257,007	\$4,164,383

The accompanying notes are an integral part of these consolidated financial statements.



Table of Contents**Physicians Realty L.P.****Consolidated Statements of Income***(In thousands, except unit and per unit data) (Unaudited)*

	Three Months Ended March 31,	
	2018	2017
<b>Revenues:</b>		
Rental revenues	\$78,887	\$ 59,092
Expense recoveries	24,308	16,354
Interest income on real estate loans and other	2,028	1,220
Total revenues	105,223	76,666
<b>Expenses:</b>		
Interest expense	16,494	9,815
General and administrative	8,459	4,736
Operating expenses	30,459	22,089
Depreciation and amortization	38,576	27,933
Acquisition expenses	—	5,405
Total expenses	93,988	69,978
<b>Income before equity in income of unconsolidated entities and gain on sale of investment properties:</b>	11,235	6,688
Equity in income of unconsolidated entities	28	28
Gain on sale of investment properties	69	—
Net income	11,332	6,716
Net income attributable to noncontrolling interests - partially owned properties (1)	(111 )	(167 )
Net income attributable to controlling interests	11,221	6,549
Preferred distributions	(487 )	(211 )
<b>Net income attributable to common unitholders</b>	<b>\$10,734</b>	<b>\$ 6,338</b>
Net income per common unit:		
Basic	\$0.06	\$ 0.04
Diluted	\$0.06	\$ 0.04
Weighted average common units:		
Basic	187,264,064	182,172,746
Diluted	187,317,243	182,605,930
Distributions declared per common unit	\$0.230	\$ 0.225

(1) An adjustment of \$0.1 million was required for net income attributable to redeemable noncontrolling interests for the three months ended March 31, 2018 and March 31, 2017.

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

**Physicians Realty L.P.**  
**Consolidated Statements of Comprehensive Income**  
*(In thousands) (Unaudited)*

	Three Months Ended	
	March 31,	
	2018	2017
Net income	\$11,332	\$6,716
Other comprehensive income:		
Change in fair value of interest rate swap agreements	4,298	825
Total other comprehensive income	4,298	825
Comprehensive income	15,630	7,541
Comprehensive income attributable to noncontrolling interests - partially owned properties	(111 )	(167 )
Comprehensive income attributable to common unitholders	\$15,519	\$7,374

The accompanying notes are an integral part of these consolidated financial statements.



Table of Contents

**Physicians Realty L.P.**  
**Consolidated Statement of Changes in Capital**  
*(In thousands) (Unaudited)*

	General Partner	Limited Partner	Accumulated Other Comprehensive Income	Total Partners' Capital	Partially Owned Properties Noncontrolling Interest	Total Partners' Capital
Balance at January 1, 2018	2,459,220	73,844	13,952	2,547,016	618	2,547,634
Net proceeds from sale of common shares	5,316	—	—	5,316	—	5,316
Restricted share award grants, net	933	—	—	933	—	933
Conversion of OP Units	126	(126 )	—	—	—	—
OP Units - distributions	(41,910 )	(1,216 )	—	(43,126 )	—	(43,126 )
Preferred distributions	(487 )	—	—	(487 )	—	(487 )
Distributions	—	—	—	—	(43 )	(43 )
Change in market value of Redeemable Limited Partners	194	—	—	194	—	194
Buyout of Noncontrolling Interest - partially owned properties	1,276	—	—	1,276	—	1,276
Change in fair value of interest rate swap agreements	—	—	4,298	4,298	—	4,298
Net income	10,908	313	—	11,221	44	11,265
Adjustments for Limited Partners ownership in Operating Partnership	(712 )	712	—	—	—	—
Balance at March 31, 2018	\$ 2,434,864	\$ 73,527	\$ 18,250	\$ 2,526,641	\$ 619	\$ 2,527,260

The accompanying notes are an integral part of this consolidated financial statements.

Table of Contents

**Physicians Realty L.P.**  
**Consolidated Statements of Cash Flows**  
*(In thousands) (Unaudited)*

	<b>Three Months Ended March 31,</b>	
	<b>2018</b>	<b>2017</b>
<b>Cash Flows from Operating Activities:</b>		
Net income	\$11,332	\$6,716
Adjustments to reconcile net income to net cash provided by operating activities		
Depreciation and amortization	38,576	27,933
Amortization of deferred financing costs	618	549
Amortization of lease inducements and above/below-market lease intangibles	1,190	1,307
Straight-line rental revenue/expense	(6,450 )	(4,508 )
Amortization of discount on unsecured senior notes	142	20
Amortization of above market assumed debt	(16 )	(59 )
Gain on sale of investment properties	(69 )	—
Equity in income of unconsolidated entities	(28 )	(28 )
Distributions from unconsolidated entities	26	55
Change in fair value of derivative	2	165
Provision for bad debts	(141 )	(127 )
Non-cash share compensation	2,605	1,490
Net change in fair value of contingent consideration	—	(70 )
Change in operating assets and liabilities:		
Tenant receivables	5,437	2,703
Other assets	(222 )	(287 )
Accounts payable	(8,461 )	(1,297 )
Accrued expenses and other liabilities	(3,651 )	(676 )
<b>Net cash provided by operating activities</b>	<b>40,890</b>	<b>33,886</b>
<b>Cash Flows from Investing Activities:</b>		
Proceeds on sales of investment properties	2,440	—
Acquisition of investment properties, net	(84,202 )	(174,737 )
Escrowed cash - acquisition deposits / earnest deposits	(2,720 )	1,375
Capital expenditures on existing investment properties	(5,608 )	(3,434 )
Issuance of real estate loans receivable	(2,000 )	(2,279 )
Repayment of real estate loan receivable	6,717	1,507
Issuance of note receivable	(20,385 )	—
Repayment of note receivable	—	16,423
Leasing commissions	(664 )	(552 )
Lease inducements	—	(2,050 )
<b>Net cash used in investing activities</b>	<b>(106,422)</b>	<b>(163,747 )</b>
<b>Cash Flows from Financing Activities:</b>		
Net proceeds from sale of common shares	5,316	301,572
Proceeds from credit facility borrowings	166,000	128,000
Payment on credit facility borrowings	(24,000 )	(529,000 )
Proceeds from issuance of senior unsecured notes	—	396,108
Principal payments on mortgage debt	(32,157 )	(5,823 )
Debt issuance costs	(412 )	(651 )
OP Unit distributions - General Partner	(42,251 )	(30,945 )
OP Unit distributions - Limited Partner	(1,232 )	(703 )

## Edgar Filing: Physicians Realty Trust - Form 10-Q

Preferred OP Units distributions - Limited Partner	(81 )	(480 )
Contributions from noncontrolling interest	—	47
Distributions to noncontrolling interest - partially owned properties	(127 )	(154 )
Payments of employee taxes for withheld stock based compensation shares	(1,701 )	(2,431 )
Purchase of Series A Preferred Units	—	(19,961 )
Purchase of Limited Partner Units	—	(3,725 )
<b>Net cash provided by financing activities</b>	<b>69,355</b>	<b>231,854</b>
Net increase in cash and cash equivalents	3,823	101,993
Cash and cash equivalents, beginning of period	2,727	15,491
<b>Cash and cash equivalents, end of period</b>	<b>\$6,550</b>	<b>\$117,484</b>
Supplemental disclosure of cash flow information - interest paid during the period	\$19,230	\$10,764
Supplemental disclosure of noncash activity - change in fair value of interest rate swap agreements	\$4,298	\$825
Supplemental disclosure of noncash activity - assumed debt	\$—	\$26,379
Supplemental disclosure of noncash activity - issuance of OP Units and Series A Preferred Units in connection with acquisitions	\$22,651	\$44,978

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

**Physicians Realty Trust and Physicians Realty L.P.  
Notes to Consolidated Financial Statements**

*Unless otherwise indicated or unless the context requires otherwise the use of the words “we,” “us,” “our,” and the “Company,” refer to Physicians Realty Trust, together with its consolidated subsidiaries, including Physicians Realty L.P.*

**Note 1. Organization and Business**

Physicians Realty Trust (the “Trust”) was organized in the state of Maryland on April 9, 2013. As of March 31, 2018, the Trust was authorized to issue up to 500,000,000 common shares of beneficial interest, par value \$0.01 per share (“common shares”). The Trust filed a Registration Statement on Form S-11 with the Securities and Exchange Commission (the “Commission”) with respect to a proposed underwritten initial public offering (the “IPO”) and completed the IPO of its common shares and commenced operations on July 24, 2013.

The Trust contributed the net proceeds from the IPO to Physicians Realty L.P., a Delaware limited partnership, (the “Operating Partnership”), and is the sole general partner of the Operating Partnership. The Trust and the Operating Partnership are managed and operated as one entity. The Trust has no significant assets other than its investment in the Operating Partnership. The Trust’s operations are conducted through the Operating Partnership and wholly-owned and majority-owned subsidiaries of the Operating Partnership. The Trust, as the general partner of the Operating Partnership, controls the Operating Partnership and consolidates the assets, liabilities, and results of operations of the Operating Partnership. Therefore, the assets and liabilities of the Trust and the Operating Partnership are the same.

The Trust is a self-managed real estate investment trust (“REIT”) formed primarily to acquire, selectively develop, own, and manage healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems.

**ATM Program**

On August 5, 2016, the Trust and the Operating Partnership entered into separate At Market Issuance Sales Agreements (the “Sales Agreements”) with each of KeyBanc Capital Markets Inc., Credit Agricole Securities (USA) Inc., JMP Securities LLC, Raymond James & Associates, Inc., and Stifel Nicolaus & Company, Incorporated (the “Agents”), pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to \$300.0 million, through the Agents (the “ATM Program”). In accordance with the Sales Agreements, the Trust may offer and sell its common shares through any of the Agents, from time to time, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, which includes sales made directly on the New York Stock Exchange or other existing trading market, or sales made to or through a market maker. With the Trust’s express written consent, sales may also be made in negotiated transactions or any other method permitted by law.

During the quarterly period ended March 31, 2018, the Trust sold 311,786 common shares pursuant to the ATM Program, at a weighted average price of \$17.85 per share, resulting in total net proceeds of approximately \$5.5 million.

As of April 30, 2018, the Trust has \$168.2 million remaining available under the ATM Program.

**Note 2. Summary of Significant Accounting Policies**

The accompanying unaudited consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the periods ended March 31, 2018 and 2017 pursuant

Edgar Filing: Physicians Realty Trust - Form 10-Q

to the instructions to Form 10-Q and Article 10 of Regulation S-X. All such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited financial statements included in the Trust’s and the Operating Partnership’s combined Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Commission on March 1, 2018.

Table of Contents

*Principles of Consolidation*

GAAP requires us to identify entities for which control is achieved through means other than voting rights and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). ASC 810 broadly defines a VIE as an entity in which either (i) the equity investors as a group, if any, lack the power through voting or similar rights to direct the activities of such entity that most significantly impact such entity’s economic performance or (ii) the equity investment at risk is insufficient to finance that entity’s activities without additional subordinated financial support. We identify the primary beneficiary of a VIE as the enterprise that has both of the following characteristics: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance, and (ii) the obligation to absorb losses or receive benefits of the VIE that could potentially be significant to the entity. We consolidate our investment in a VIE when we determine that we are the VIE’s primary beneficiary. We may change our original assessment of a VIE upon subsequent events such as the modification of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposition of all or a portion of an interest held by the primary beneficiary. We perform this analysis on an ongoing basis.

For property holding entities not determined to be VIEs, we consolidate such entities in which the Operating Partnership owns 100% of the equity or has a controlling financial interest evidenced by ownership of a majority voting interest. All intercompany balances and transactions are eliminated in consolidation. For entities in which the Operating Partnership owns less than 100% of the equity interest, the Operating Partnership consolidates the property if it has the direct or indirect ability to control the entities’ activities based upon the terms of the respective entities’ ownership agreements. For these entities, the Operating Partnership records a noncontrolling interest representing equity held by noncontrolling interests.

*Noncontrolling Interests*

The Company presents the portion of any equity it does not own in entities that it controls (and thus consolidates) as noncontrolling interests and classifies such interests as a component of consolidated equity, separate from the Company’s total shareholders’ equity, on the consolidated balance sheets.

Operating Partnership: Net income or loss is allocated to noncontrolling interests (limited partners) based on their respective ownership percentage of the Operating Partnership. The ownership percentage is calculated by dividing the number of OP Units held by the noncontrolling interests by the total OP Units held by the noncontrolling interests and the Trust. Issuance of additional common shares and OP Units changes the ownership interests of both the noncontrolling interests and the Trust. Such transactions and the related proceeds are treated as capital transactions.

Noncontrolling interests in the Company include OP Units held by other investors. As of March 31, 2018, the Trust held a 97.1% interest in the Operating Partnership. As the sole general partner and the majority interest holder, the Trust consolidates the financial position and results of operations of the Operating Partnership.

Holders of OP Units may not transfer their OP Units without the Trust’s prior written consent, as general partner of the Operating Partnership. Beginning on the first anniversary of the issuance of OP Units, OP Unit holders may tender their units for redemption by the Operating Partnership in exchange for cash equal to the market price of the Trust’s common shares at the time of redemption or for unregistered common shares on a one-for-one basis. Such selection to pay cash or issue common shares to satisfy an OP Unit holder’s redemption request is solely within the control of the Trust. Accordingly, the Trust presents the OP Units of the Operating Partnership held by investors other than the Trust as noncontrolling interests within equity in the consolidated balance sheets.

Partially Owned Properties: The Trust and Operating Partnership reflect noncontrolling interests in partially owned properties on the balance sheet for the portion of consolidated properties that are not wholly owned by the Company.

Edgar Filing: Physicians Realty Trust - Form 10-Q

The earnings or losses from those properties attributable to the noncontrolling interests are reflected as noncontrolling interests in partially owned properties in the consolidated statements of income.

Table of Contents

*Redeemable Noncontrolling Interests - Series A Preferred Units and Partially Owned Properties*

On February 5, 2015, the Company entered into a Second Amended and Restated Agreement of Limited Partnership (the “Partnership Agreement”) which provides for the designation and issuance of the newly designated Series A Participating Redeemable Preferred Units of the Operating Partnership (“Series A Preferred Units”). Series A Preferred Units have priority over all other partnership interests of the Operating Partnership with respect to distributions and liquidation. Holders of Series A Preferred Units are entitled to a 5% cumulative return and upon redemption, the receipt of one common share and \$200. The holders of the Series A Preferred Units have agreed not to cause the Operating Partnership to redeem their Series A Preferred Units prior to one year from the issuance date. In addition, Series A Preferred Units are redeemable at the option of the holders which redemption obligation may be satisfied, at the Trust’s option, in cash or registered common shares. Instruments that require settlement in registered common shares may not be classified in permanent equity as it is not always completely within an issuer’s control to deliver registered common shares. Due to the redemption rights associated with the Series A Preferred Units, the Company classifies the Series A Preferred Units in the mezzanine section of the consolidated balance sheets.

The Series A Preferred Units were evaluated for embedded features that should be bifurcated and separately accounted for as a freestanding derivative. The Company determined that the Series A Preferred Units contained features that require bifurcation. The Company records the carrying amount of the redeemable noncontrolling interests, less the value of the embedded derivative, at the greater of the carrying value or redemption value in the consolidated balance sheets.

On January 9, 2018, the acquisition of the HealthEast Clinic & Specialty Center (“Hazelwood Medical Commons”) was partially funded with the issuance of 104,172 Series A Preferred Units with a value of \$22.7 million. Due to the redemption rights associated with the Series A Preferred Units the Trust classifies the Series A Preferred Units in the mezzanine section of its consolidated balance sheet. As of March 31, 2018, the value of the embedded derivative is \$3.8 million and is classified in accrued expenses and other liabilities on the consolidated balance sheet.

As of March 31, 2018, there were 104,172 Series A Preferred Units outstanding.

In connection with the acquisition of a medical office portfolio in Minnesota (the “Minnesota portfolio”), the Trust received a \$5 million equity investment from a third party, effective March 1, 2015. This investment earns a 15% cumulative preferred return. At any point subsequent to the third anniversary of the investment, the holder can require the Trust to redeem the instrument at a price for which the investor will realize a 15% internal rate of return. Due to the redemption provision, which is outside of the control of the Trust, the Trust classifies the investment in the mezzanine section of its consolidated balance sheet. The Trust records the carrying amount of the redeemable noncontrolling interests at the greater of the carrying value or redemption value. As of March 1, 2018, holders redeemed a portion of their noncontrolling interest for \$6.4 million.

In connection with the acquisition on December 29, 2015 of a medical office building located on the campus of the Great Falls Clinic and Hospital in Great Falls, Montana, physicians affiliated with the seller retained a noncontrolling interest which may, at the holders’ option, be redeemed at any time. Due to the redemption provision, which is outside of the control of the Trust, the Trust classifies the investment in the mezzanine section of its consolidated balance sheet. The Trust records the carrying amount of the redeemable noncontrolling interests at the greater of the carrying value or redemption value.

*Dividends and Distributions*

On March 23, 2018, the Trust announced that its Board of Trustees authorized and the Trust declared a cash dividend of \$0.23 per common share for the quarterly period ended March 31, 2018. The distribution was paid on April 18,



## Edgar Filing: Physicians Realty Trust - Form 10-Q

2018 to common shareholders and OP Unit holders of record as of the close of business on April 3, 2018.

All distributions paid by the Operating Partnership are declared and paid at the same time as dividends are distributed by the Trust to common shareholders. It has been the Operating Partnership's policy to declare quarterly distributions so as to allow the Trust to comply with applicable provisions of the Internal Revenue Code of 1986, as amended (the "Code"), governing REITs. The declaration and payment of quarterly distributions remains subject to the review and approval of the Trust's Board of Trustees.

Our shareholders are entitled to reinvest all or a portion of any cash distribution on their common shares by participating in our Dividend Reinvestment and Share Purchase Plan ("DRIP"), subject to the terms of the plan.

Table of Contents

*Tax Status of Dividends and Distributions*

Our distributions of current and accumulated earnings and profits for U.S. federal income tax purposes generally are taxable to shareholders as ordinary income. Distributions in excess of these earnings and profits generally are treated as a non-taxable reduction of the shareholders' basis in the shares to the extent thereof (non-dividend distributions) and thereafter as taxable gain.

Any cash distributions received by an OP Unit holder in respect of its OP Units generally will not be taxable to such OP Unit holder for U.S. federal income tax purposes, to the extent that such distribution does not exceed the OP Unit holder's basis in its OP Units. Any such distribution will instead reduce the OP Unit holder's basis in its OP Units (and OP Unit holders will be subject to tax on the taxable income allocated to them by the Operating Partnership in respect of their OP Units when such income is earned by the Operating Partnership, with such income allocation increasing the OP Unit holders' basis in their OP Units).

*Purchases of Investment Properties*

With the adoption of ASU 2017-01 in January 2018 we expect the majority of our future investments in real estate investments will be accounted for as asset acquisitions and to record the purchase price to tangible and intangible assets and liabilities based on their relative fair values. Tangible assets primarily consist of land and buildings and improvements. Additionally, the purchase price includes acquisition related expenses, above- or below-market leases, in place leases, above- or below-market debt assumed, and any contingent consideration recorded when the contingency is resolved. The determination of the fair value requires us to make certain estimates and assumptions.

The determination of fair value involves the use of significant judgment and estimation. The Company makes estimates of the fair value of the tangible and intangible acquired assets and assumed liabilities using information obtained from multiple sources as a result of pre-acquisition due diligence and generally includes the assistance of a third party appraiser. The Company estimates the fair value of an acquired asset on an "as-if-vacant" basis and its value is depreciated in equal amounts over the course of its estimated remaining useful life. The Company determines the allocated value of other fixed assets, such as site improvements, based upon the replacement cost and depreciates such value over the assets' estimated remaining useful lives as determined at the applicable acquisition date. The fair value of land is determined either by considering the sales prices of similar properties in recent transactions or based on internal analyses of recently acquired and existing comparable properties within the Company's portfolio.

The value of above- or below-market leases is estimated based on the present value (using an interest rate which reflected the risks associated with the leases acquired) of the difference between contractual amounts to be received pursuant to the leases and management's estimate of market lease rates measured over a period equal to the estimated remaining term of the lease. The capitalized above-market or below-market lease intangibles are amortized as a reduction or addition to rental income over the estimated remaining term of the respective leases plus the term of any renewal options that the lessee would be economically compelled to exercise.

In determining the value of in-place leases, management considers current market conditions and costs to execute similar leases in arriving at an estimate of the carrying costs during the expected lease-up period from vacant to existing occupancy. In estimating carrying costs, management includes real estate taxes, insurance, other operating expenses, estimates of lost rental revenue during the expected lease-up periods, and costs to execute similar leases, including leasing commissions, tenant improvements, legal, and other related costs based on current market demand. The values assigned to in-place leases are amortized to amortization expense over the estimated remaining term of the lease. If a lease terminates prior to its scheduled expiration, all unamortized costs related to that lease are written off, net of any required lease termination payments.

## Edgar Filing: Physicians Realty Trust - Form 10-Q

The Company calculates the fair value of any long-term debt assumed by discounting the remaining contractual cash flows on each instrument at the current market rate for those borrowings, which the Company approximates based on the rate it would expect to incur on a replacement instrument on the date of acquisition, and recognizes any fair value adjustments related to long-term debt as effective yield adjustments over the remaining term of the instrument.

Based on these estimates, the Company recognizes the acquired assets and assumed liabilities at their estimated fair values, which are generally determined using Level 3 inputs, such as market rental rates, capitalization rates, discount rates, or other available market data. Initial valuations are subject to change until the information is finalized, no later than 12 months from the acquisition date.

## Table of Contents

### *Impairment of Intangible and Long-Lived Assets*

The Company periodically evaluates its long-lived assets, primarily consisting of investments in real estate, for impairment indicators or whenever events or changes in circumstances indicate that the recorded amount of an asset may not be fully recoverable. If indicators of impairment are present, the Company evaluates the carrying value of the related real estate properties in relation to the undiscounted expected future cash flows of the underlying operations. In performing this evaluation, management considers market conditions and current intentions with respect to holding or disposing of the real estate property. The Company adjusts the net book value of real estate properties to fair value if the sum of the expected future undiscounted cash flows, including sales proceeds, is less than book value. The Company recognizes an impairment loss at the time it makes any such determination. If the Company determines that an asset is impaired, the impairment to be recognized is measured as the amount by which the recorded amount of the asset exceeds its fair value. Fair value is typically determined using a discounted future cash flow analysis or other acceptable valuation techniques, which are based, in turn, upon Level 3 inputs, such as revenue and expense growth rates, capitalization rates, discount rates, or other available market data.

The Company did not record any impairment charges in the three month periods ended March 31, 2018 and 2017.

### *Assets Held for Sale*

The Company may sell properties from time to time for various reasons, including favorable market conditions. The Company classifies certain long-lived assets as held for sale once the criteria, as defined by GAAP, has been met. The Company classifies a real estate property, or portfolio, as held for sale when: (i) management has approved the disposal, (ii) the property is available for sale in its present condition, (iii) an active program to locate a buyer has been initiated, (iv) it is probable that the property will be disposed of within one year, (v) the property is being marketed at a reasonable price relative to its fair value, and (vi) it is unlikely that the disposal plan will significantly change or be withdrawn. Following the classification of a property as “held for sale,” no further depreciation is recorded on the assets, and the asset is written down to the lower of carrying value or fair market value, less cost to sell. As of March 31, 2018, the Company classified one disposition group as held for sale which includes 15 medical office buildings.

### *Investments in Unconsolidated Entities*

The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in its consolidated statements of income. The initial carrying value of investments in unconsolidated entities is based on the amount paid to purchase the equity interest.

### *Real Estate Loans Receivable*

Real estate loans receivable consists of ten mezzanine loans and two term loans as of March 31, 2018. Generally, each mezzanine loan is collateralized by an ownership interest in the respective borrower, while each term loan is secured by a mortgage of a related medical office building. Interest income on the loans is recognized as earned based on the terms of the loans, subject to evaluation of collectability risks, and is included in the Company’s consolidated statements of income. On a quarterly basis, the Company evaluates the collectability of its loan portfolio, including related interest income receivable, and establishes a reserve for loan losses, if necessary. No such losses have been recognized to date.

### *Rental Revenue*

Rental revenue is recognized on a straight-line basis over the terms of the related leases when collectability is reasonably assured. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue for amounts more or less than amounts currently due from tenants. Amounts recognized in excess of amounts currently due from tenants, excluding assets classified as held for sale, net of related allowances, are included in other assets and were approximately \$51.0 million and \$47.6 million as of March 31, 2018 and December 31, 2017, respectively. If the Company determines that collectability of straight-line rents is not reasonably assured, the Company limits future recognition to amounts contractually owed and, where appropriate, establishes an allowance for estimated losses. Allowance for doubtful accounts was approximately \$0.3 million and \$4.9 million as of March 31, 2018 and December 31, 2017, respectively. Rental revenue is adjusted by amortization of lease inducements and above or below market rents on certain leases. Lease inducements and above or below market rents are amortized over the remaining life of the lease.

## Table of Contents

### *Expense Recoveries*

Expense recoveries relate to tenant reimbursement of real estate taxes, insurance, and other operating expenses that are recognized as expense recovery revenue in the period the applicable expenses are incurred. The reimbursements are recorded at gross, as the Company is generally the primary obligor with respect to real estate taxes and purchasing goods and services from third-party suppliers, has discretion in selecting the supplier, and bears the credit risk of tenant reimbursement.

The Company has certain tenants with absolute net leases. Under these lease agreements, the tenant is responsible for operating and building expenses. For absolute net leases, the Company does not recognize expense recoveries.

### *Derivative Instruments*

When the Company has derivative instruments embedded in other contracts, it records them either as an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sale exception. When specific hedge accounting criteria are not met, changes in the Company's derivative instruments' fair value are recognized currently in earnings. Changes in the fair market values of the Company's derivative instruments are recorded in the consolidated statements of income if the derivative instruments do not qualify for, or the Company does not elect to apply for, hedge accounting. If hedge accounting is applied to a derivative instrument, such changes are reported in accumulated other comprehensive income within the consolidated statement of equity, exclusive of ineffectiveness amounts, which are recognized as adjustments to net income.

To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of March 31, 2018, the Company had five outstanding interest rate swap contracts that are designated as cash flow hedges of interest rate risk. For presentational purposes, they are shown as one derivative due to the identical nature of their economic terms. Further detail is provided in Note 7 (Derivatives).

The effective portion of the change in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income ("AOCI") on the consolidated balance sheets and is subsequently reclassified into earnings as interest expense for the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. For the three months ended March 31, 2018, hedge ineffectiveness was insignificant. For the three months ended March 31, 2017, the Company recorded a \$0.2 million loss as a result of hedge ineffectiveness. The Company expects hedge ineffectiveness to be insignificant in the next 12 months.

### *Income Taxes*

The Trust elected to be taxed as a REIT for federal tax purposes commencing with the filing of its tax return for the short taxable year ending December 31, 2013. The Trust had no taxable income prior to electing REIT status. To qualify as a REIT, the Trust must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of its annual REIT taxable income to its shareholders (which is computed without regard to the dividends paid deduction or net capital gain and which does not necessarily equal net income as calculated in accordance with GAAP). As a REIT, the Trust generally will not be subject to federal income tax to the extent it distributes qualifying dividends to its shareholders. If the Trust fails to qualify as a REIT in any taxable year, it will be subject to federal income tax (including any applicable alternative minimum tax) on its taxable income at regular

corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost, unless the Internal Revenue Service grants the Trust relief under certain statutory provisions. Such an event could materially adversely affect the Trust's net income and net cash available for distribution to shareholders. However, the Trust intends to continue to operate in such a manner as to continue qualifying for treatment as a REIT. Although the Trust continues to qualify for taxation as a REIT, in various instances, the Trust is subject to state and local taxes on its income and property, and federal income and excise taxes on its undistributed income.

As discussed in Note 1 (Organization and Business), the Trust conducts substantially all of its operations through the Operating Partnership. As a partnership, the Operating Partnership generally is not liable for federal income taxes. The income and loss from the operations of the Operating Partnership is included in the tax returns of its partners, including the Trust, who are responsible for reporting their allocable share of the partnership income and loss. Accordingly, no provision for income taxes has been made on the accompanying consolidated financial statements.

## Table of Contents

### *Tenant Receivables, Net*

Tenant accounts receivable are stated net of the applicable allowance. Rental payments under these contracts are primarily due monthly. The Company assesses the collectability of tenant receivables, including straight-line rent receivables, and defers recognition of revenue if collectability is not reasonably assured. The Company bases its assessment of the collectability of rent receivables on several factors, including, among other things, payment history, the financial strength of the tenant, and current economic conditions. If management's evaluation of these factors indicates it is probable that the Company will be unable to recover the full value of the receivable, the Company provides a reserve against the portion of the receivable that it estimates may not be recovered. At March 31, 2018 and December 31, 2017, the allowance for doubtful accounts was \$0.8 million and \$1.6 million, respectively.

### *Management Estimates*

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the amounts of revenue and expenses reported in the period. Significant estimates are made for the fair value assessments with respect to purchase price allocations, impairment assessments, and the valuation of financial instruments. Actual results could differ from these estimates.

### *Contingent Liabilities*

Certain of our acquisitions provide for additional consideration to the seller in the form of an earn-out associated with lease-up contingencies. The Company recognizes the contingent liabilities only if certain parameters or other substantive contingencies are met, at which time the consideration becomes payable. Resolved contingent liabilities increase our acquired assets, and reduce our liability.

In January 2017, the FASB issued ASU No. 2017-01, *Clarifying the Definition of a Business*, which changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. Prior to January 1, 2018, the Company recorded certain contingent liabilities which are included in accrued expenses and other liabilities on its consolidated balance sheets. These were recorded at fair value as of the acquisition date and until they expire, the Company reassesses the fair value at the end of each reporting period, with any changes being recognized in earnings.

### *Reclassifications*

Certain prior period amounts have been reclassified to conform to the current financial statement presentation, with no effect on the previously reported consolidated balance sheets or consolidated statements of income.

### *Segment Reporting*

Under the provision of Codification Topic 280, *Segment Reporting*, the Company has determined that it has one reportable segment with activities related to leasing and managing healthcare properties.

### *New Accounting Pronouncements*

In May 2014, the FASB issued ASU 2014-09, *Revenue from Contracts with Customers*, which creates a new Topic, Accounting Standards Codification Topic 606. The standard is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company



expects to be entitled in exchange for those goods or services. We adopted ASU 2014-09 as of January 1, 2018 under the modified retrospective approach. Based on our assessment, we have identified all of our revenue streams and concluded rental income from leasing arrangements represents a substantial portion of our revenue. Income from leasing arrangements is specifically excluded from Topic 606 and will be evaluated with the anticipated adoption of ASU 2016-02, *Leases*. Therefore, the impact of adopting ASU 2014-09 was minimal on our current recognition and presentation of non-lease revenue. Upon adoption of ASU 2016-02, Topic 606 may apply to executory costs and other components of revenue due under leases that are deemed to be non-lease components (such as common area maintenance and other reimbursement revenue), even when the revenue for such activities is not separately stipulated in the lease. In that case, the revenue from these items previously recognized on a straight-line basis under the current lease guidance would be recognized under the new revenue guidance as the related services are delivered.

Table of Contents

In February 2016, the FASB issued ASU 2016-02, *Leases*. The update amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. The standard provides the option of a modified retrospective transition approach or a cumulative effect for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The FASB also issued an Exposure Draft on January 5, 2018 proposing to amend ASU 2016-02, which would provide lessors with a practical expedient, by class of underlying assets, to not separate non-lease components from the related lease components and, instead, to account for those components as a single lease component, if certain criteria are met. ASU 2016-02 and the related Exposure Draft are not effective for us until January 1, 2019, with early adoption permitted. We are continuing to evaluate this guidance and the impact to us, as both lessor and lessee, on our Consolidated Financial Statements. We expect to utilize the practical expedients proposed in the Exposure Draft as part of our adoption of ASU 2016-02. As a result of adopting the practical expedients, the Company will recognize all of its operating leases for which it is the lessee, including ground leases, on its consolidated balance sheets. The Company is evaluating the impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments-Credit Losses*, which changes the impairment model for most financial instruments by requiring companies to recognize an allowance for expected losses, rather than incurred losses as required currently by the other-than-temporary impairment model. ASU 2016-13 will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases, and off-balance-sheet credit exposures (e.g., loan commitments). ASU 2016-13 is effective for reporting periods beginning after December 15, 2019, with early adoption permitted, and will be applied as a cumulative adjustment to retained earnings as of the effective date. We are currently assessing the potential effect the adoption of ASU 2016-13 will have on our consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, *Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payment*. ASU 2016-15 clarifies the guidance on the classification of certain cash receipts and payments in the statement of cash flows to reduce diversity in practice with respect to: (i) debt prepayment or debt extinguishment costs; (ii) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (iii) contingent consideration payments made after a business combination; (iv) proceeds from the settlement of insurance claims; (v) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (vi) distributions received from equity method investees; (vii) beneficial interests in securitization transactions; and (viii) separately identifiable cash flows and application of the predominance principle. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. The Company adopted ASU 2016-15 on January 1, 2018, with no material effect on its consolidated financial statements and no adjustments made to prior periods.

In November 2016, the FASB issued ASU 2016-18, *Statement of Cash Flows: Restricted Cash*, which will require companies to include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows. ASU 2016-18 will require disclosure of a reconciliation between the balance sheet and the statement of cash flows when the balance sheet includes more than one line item for cash, cash equivalents, restricted cash, and restricted cash equivalents. An entity with material restricted cash and restricted cash equivalents balances will be required to disclose the nature of the restrictions. ASU 2016-18 is effective for reporting periods beginning after December 15, 2017, and is required to be applied retrospectively to all periods presented. The Company adopted ASU 2016-18 on January 1, 2018, with no material effect on its consolidated financial statements and no adjustments made to prior periods.

In January 2017, the FASB issued ASU No. 2017-01, *Clarifying the Definition of a Business*, which changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business.

ASU 2017-01 states that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not a business. If this initial test is not met, a set cannot be considered a business unless it includes an acquired input and a substantive process that together significantly contribute to the ability to create outputs. In addition, ASU 2017-01 clarifies the requirements for a set of activities to be considered a business and narrows the definition of an output. This ASU is to be applied prospectively and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted ASU 2017-01 on January 1, 2018 and as a result, have classified our real estate acquisitions completed during the three months ended March 31, 2018 as asset acquisitions rather than business combinations due to the fact that substantially all of the fair value of the gross assets acquired were concentrated in a single asset or group of similar identifiable assets. The Company has recorded identifiable assets acquired, liabilities assumed and any noncontrolling interests associated with any asset acquisitions at cost on a relative fair value basis and has capitalized transaction costs incurred.

Table of Contents

In August 2017, the FASB issued ASU 2017-12, *Derivatives and Hedging: Targeted Improvements to Accounting for Hedging Activities*, which expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. It also includes certain targeted improvements to simplify the application of current guidance related to hedge accounting. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently in the process of evaluating the effects this standard will have on its consolidated financial statements.

**Note 3. Acquisitions and Dispositions**

During the three months ended March 31, 2018, the Company completed acquisitions of 2 operating healthcare properties and 1 land parcel located in 3 states for an aggregate purchase price of approximately \$99.4 million. In addition, the Company completed a noncontrolling interest buyout for \$6.4 million and a \$2.0 million loan transaction, resulting in total investment activity of approximately \$107.8 million.

Effective January 1, 2018, with our adoption of ASU 2017-01, transaction costs incurred for asset acquisitions are capitalized as a component of purchase price and all other non-capitalizable costs are reflected in "Operating Expenses" on our consolidated statement of operations. Certain acquisitions that occurred prior to January 1, 2018, were accounted for as business combinations.

Investment activity for the three months ended March 31, 2018 is summarized below:

Property	Location	Acquisition Date	Purchase Price (in thousands)
Hazelwood Medical Commons	(1) Maplewood, MN	January 9, 2018	\$ 70,702
Lee's Hill Medical Plaza	Fredericksburg, VA	January 23, 2018	28,000
Scottsdale, Arizona Land	(2) Scottsdale, AZ	February 16, 2018	700
Loan Investment	(3) Pensacola, FL	February 16, 2018	2,000
Noncontrolling Interest Buyout - Minnesota portfolio	(4)	March 1, 2018	6,406
			\$ 107,808

(1) The Company partially funded the purchase price of this acquisition by issuing a total of 104,172 Series A Preferred Units valued at approximately \$22.7 million in the aggregate on the date of issuance.

(2) The Company acquired the land beneath a previously acquired facility.

(3) Has an interest rate of 8.9%.

(4) The Company acquired an additional 4.2% interest in the Minnesota portfolio joint venture, increasing the Company's total interest in the joint venture to 99.6%.

For the three months ended March 31, 2018, the Company recorded revenues and net income from its 2018 acquisitions of \$1.9 million and \$0.6 million, respectively.

The following table summarizes the acquisition date fair values of the assets acquired and the liabilities assumed, which the Company determined using Level 2 and Level 3 inputs (in thousands):

Land	\$7,684
Building and improvements	82,180
In-place lease intangible	13,202
Above market in-place lease intangible	969
Below market in-place lease intangible	(959 )
Prepaid Expenses	(2,628 )
Issuance of Series A Preferred Units	(22,651 )
Net assets acquired	\$77,797



Table of Contents*Dispositions*

During the three months ended March 31, 2018, the Company sold two medical office buildings located in Michigan and Florida for approximately \$2.5 million and recognized a net gain on the sale of approximately \$0.1 million.

The following table summarizes revenues and net income related to the two disposed properties for the periods presented (in thousands):

	Three Months Ended	
	March 31,	
	2018	2017
Revenues	\$48	\$142
Income (loss) before gain on sale of investment properties:	(46 )	29
Gain on sale of investment properties, net	69	—
Net income	\$23	\$29

*Assets Held for Sale*

As of March 31, 2018, the Company classified one portfolio comprised of 15 properties, as held for sale. In accordance with this classification, the following assets are classified as held for sale in the accompanying consolidated balance sheets at March 31, 2018.

Land and improvements	\$10,166
Building and improvements	80,517
Tenant improvements	6,046
Acquired lease intangibles	12,967
Other Assets	3,898
Real estate held for sale before accumulated depreciation	113,594
Accumulated depreciation	(20,305 )
Real estate held for sale	\$93,289

*Unaudited Pro Forma Financial Information**Physicians Realty Trust*

The following table illustrates the pro forma consolidated revenue, net income, and earnings per share as if the Company had acquired the 2018 acquisitions as of January 1, 2017 (in thousands, except share and per share amounts):

	Three Months Ended	
	March 31,	
	2018	2017
Revenue	\$106,047	\$ 79,183
Net income	12,009	7,298
Net income available to common shareholders	11,065	6,756
Earnings per share - basic	\$0.06	\$ 0.04
Earnings per share - diluted	\$0.06	\$ 0.04
Weighted average number of shares outstanding - basic	181,809,570	181,809,570
Weighted average number of shares outstanding - diluted	187,317,243	187,317,243



Table of Contents*Physicians Realty L.P.*

The following table illustrates the pro forma consolidated revenue, net income, and earnings per unit as if the Company had acquired the 2018 acquisitions as of January 1, 2017 (in thousands, except unit and per unit amounts):

	Three Months Ended March 31,	
	2018	2017
Revenue	\$ 106,047	\$ 79,183
Net income	12,009	7,298
Net income available to common unitholders	11,411	6,920
Earnings per unit - basic	\$0.06	\$ 0.04
Earnings per unit - diluted	\$0.06	\$ 0.04
Weighted average number of units outstanding - basic	187,264,064	187,264,064
Weighted average number of units outstanding - diluted	187,317,243	187,317,243

**Note 4. Intangibles**

The following is a summary of the carrying amount of intangible assets and liabilities, excluding 15 assets classified as held for sale, as of March 31, 2018 and December 31, 2017 (in thousands):

	March 31, 2018			December 31, 2017		
	Cost	Accumulated Amortization	Net	Cost	Accumulated Amortization	Net
<b>Assets</b>						
In-place leases	\$ 345,495	\$(90,633 )	\$ 254,862	\$ 343,429	\$(85,424 )	\$ 258,005
Above-market leases	53,205	(12,680 )	40,525	54,148	(11,968 )	42,180
Leasehold interest	712	(198 )	514	712	(183 )	529
Below-market ground leases	60,424	(1,588 )	58,836	60,424	(1,344 )	59,080
Total	\$ 459,836	\$(105,099 )	\$ 354,737	\$ 458,713	\$(98,919 )	\$ 359,794
<b>Liabilities</b>						
Below-market leases	\$ 15,225	\$(5,261 )	\$ 9,964	\$ 14,344	\$(4,479 )	\$ 9,865
Above-market ground leases	5,965	(162 )	5,803	5,965	(128 )	5,837
Total	\$ 21,190	\$(5,423 )	\$ 15,767	\$ 20,309	\$(4,607 )	\$ 15,702

The following is a summary of the acquired lease intangible amortization for the three month periods ended March 31, 2018 and 2017, respectively (in thousands):

	Three Months Ended March 31,	
	2018	2017
Amortization expense related to in-place leases	\$ 11,002	\$ 8,740
Decrease of rental income related to above-market leases	1,480	1,389
Decrease of rental income related to leasehold interest	15	14
Increase of rental income related to below-market leases	843	569
Decrease of operating expense related to above-market ground leases	35	8
Increase in operating expense related to below-market ground leases	244	185





Table of Contents

Future aggregate net amortization of the acquired lease intangibles as of March 31, 2018, is as follows (in thousands):

	Net Decrease in Revenue	Net Increase in Expenses
2018	\$ (2,267 )	\$ 30,661
2019	(3,219 )	36,279
2020	(3,320 )	33,480
2021	(3,264 )	31,142
2022	(2,772 )	26,841
Thereafter	(16,233 )	149,492
Total	\$ (31,075 )	\$ 307,895

As of March 31, 2018, the weighted average amortization period for asset lease intangibles and liability lease intangibles are 19 and 20 years, respectively.

**Note 5. Other Assets**

Other assets, excluding 15 assets classified as held for sale, consisted of the following as of March 31, 2018 and December 31, 2017 (in thousands):

	March 31, 2018	December 31, 2017
Straight line rent receivable, net	\$50,952	\$47,599
Note receivable	20,606	—
Interest rate swap	18,976	14,693
Prepaid expenses	15,510	18,103
Lease inducements, net	13,943	14,232
Earnest deposits	5,500	2,780
Leasing commissions, net	4,420	4,128
Escrows	1,475	1,996
Other	3,537	2,771
Total	\$134,919	\$106,302

Table of Contents**Note 6. Debt**

The following is a summary of debt as of March 31, 2018 and December 31, 2017 (in thousands):

	March 31, 2018	December 31, 2017	
Fixed interest mortgage notes	\$ 147,607	(1) \$ 158,171	(2)
Variable interest mortgage notes	6,915	(3) 28,509	(4)
Total mortgage debt	154,522	186,680	
\$850 million unsecured revolving credit facility bearing variable interest of LIBOR plus 1.20%, due September 2020	222,000	80,000	
\$400 million senior unsecured notes bearing fixed interest of 4.30%, due March 2027	400,000	400,000	
\$350 million senior unsecured notes bearing fixed interest of 3.95%, due January 2028	350,000	350,000	
\$250 million unsecured term borrowing bearing fixed interest of 2.87%, due June 2023 (5)	250,000	250,000	
\$150 million senior unsecured notes bearing fixed interest of 4.03% to 4.74%, due January 2023 to 2031	150,000	150,000	
\$75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027	75,000	75,000	
Total principal	1,601,522	1,491,680	
Unamortized deferred financing costs	(7,657 )	(7,808 )	
Unamortized discount	(6,521 )	(6,663 )	
Unamortized fair value adjustment	244	259	
Total debt	\$ 1,587,588	\$ 1,477,468	

Fixed interest mortgage notes, bearing interest from 3.00% to 5.50%, with a weighted average interest rate (1) of 4.39%, and due in 2019, 2020, 2021, 2022, and 2024 collateralized by eight properties with a net book value of \$240.8 million.

Fixed interest mortgage notes, bearing interest from 3.00% to 5.50%, with a weighted average interest rate (2) of 4.45%, and due in 2018, 2019, 2020, 2021, 2022, and 2024 collateralized by nine properties with a net book value of \$267.7 million.

(3) Variable interest mortgage note bearing variable interest of LIBOR plus 2.25% and due in 2018, collateralized by one property with a net book value of \$8.3 million.

Variable interest mortgage notes, bearing variable interest of LIBOR plus 2.25% to 3.25%, with a weighted (4) average interest rate of 4.50% and due 2018 collateralized by three properties with a net book value of \$39.2 million.

The Trust's borrowings under the term loan feature of the Credit Agreement bear interest at a rate which is (5) determined by the Trust's credit rating, currently equal to LIBOR + 1.80%. The Trust has entered into a pay-fixed receive-variable interest rate swap, fixing the LIBOR component of this rate at 1.07%.

On June 10, 2016, the Operating Partnership, as borrower, and the Trust entered into an amended and restated Credit Agreement with KeyBank National Association, as administrative agent, KeyBanc Capital Markets Inc., BMO Capital Markets, and Citizens Bank N.A., as joint lead arrangers and co-book runners, BMO Capital Markets and Citizens Bank N.A., as co-syndication agents, and the lenders party thereto (the "Credit Agreement") which increased the maximum principal amount available under an unsecured revolving credit facility from \$750 million to \$850 million. The Credit Agreement contains a 7-year term loan feature allowing the Operating Partnership to borrow in a single drawing up to \$250 million, increasing the borrowing capacity to an aggregate \$1.1 billion. The Credit Agreement also includes a swingline loan commitment for up to 10% of the maximum principal amount and provides an accordion feature allowing the Trust to increase borrowing capacity by up to an additional \$500 million, subject to customary terms and conditions, resulting in a maximum borrowing capacity of \$1.6 billion.



Table of Contents

On July 7, 2016, the Operating Partnership borrowed \$250.0 million under the 7-year term loan feature of the Credit Agreement. Borrowings under the term loan feature of the Credit Agreement bear interest on the outstanding principal amount at a rate which is determined by the Trust's credit rating, currently equal to LIBOR + 1.80%. The Trust simultaneously entered into a pay-fixed receive-variable rate swap for the full borrowing amount, fixing the LIBOR component of the borrowing rate to 1.07%, for an all-in fixed rate of 2.87%. Both the borrowing and pay-fixed receive-variable swap have a maturity date of June 10, 2023.

The Credit Agreement has a maturity date of September 18, 2020 and includes a one year extension option. Borrowings under the Credit Agreement bear interest on the outstanding principal amount at an adjusted LIBOR rate, which is based on the Trust's investment grade rating under the Credit Agreement. As of March 31, 2018, the Trust had an investment grade rating of Baa3 from Moody's and BBB- from S&P. As such, borrowings under the revolving credit facility of the Credit Agreement accrued interest on the outstanding principal at a rate of LIBOR plus 1.20%. The Credit Agreement includes a facility fee equal to 0.25% per annum, which is also determined by the Trust's investment grade rating.

The Credit Agreement contains financial covenants that, among other things, require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as covenants that may limit the Trust's and the Operating Partnership's ability to incur additional debt or make distributions. The Company may, at any time, voluntarily prepay any revolving or swingline loan under the Credit Agreement in whole or in part without premium or penalty. Prepayments of term borrowings require payment of premiums of up to 2.0% of the amount of prepayment, dependent on the date of such prepayment. As of March 31, 2018, the Company was in compliance with all financial covenants related to the Credit Agreement.

The Credit Agreement includes customary representations and warranties by the Trust and the Operating Partnership, and imposes customary covenants on the Operating Partnership and the Trust. The Credit Agreement also contains customary events of default, and if an event of default occurs and continues, the Operating Partnership is subject to certain actions by the administrative agent, including without limitation, the acceleration of repayment of all amounts outstanding under the Credit Agreement.

The Credit Agreement provides for revolving credit and term loans to the Trust and the Operating Partnership. Base Rate Loans, Adjusted LIBOR Rate Loans, and Letters of Credit (each, as defined in the Credit Agreement) will be subject to interest rates, based upon the Trust's investment grade rating as follows:

Credit Rating	Margin for Revolving Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee	Margin for Revolving Loans: Base Rate Loans	Margin for Term Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee	Margin for Term Loans: Base Rate Loans
At Least A- or A3	LIBOR + 0.85%	— %	LIBOR + 1.40%	0.40 %
At Least BBB+ or Baa1	LIBOR + 0.90%	— %	LIBOR + 1.45%	0.45 %
At Least BBB or Baa2	LIBOR + 1.00%	0.10 %	LIBOR + 1.55%	0.55 %
At Least BBB- or Baa3	LIBOR + 1.20%	0.20 %	LIBOR + 1.80%	0.80 %
Below BBB- or Baa3	LIBOR + 1.55%	0.60 %	LIBOR + 2.25%	1.25 %

As of March 31, 2018, the company had \$222.0 million of borrowings outstanding under its unsecured revolving credit facility, and \$250.0 million of borrowings outstanding under the term loan feature of the Credit Agreement. The

Company has also issued a letter of credit for \$17.0 million with no outstanding balance as of March 31, 2018. As defined by the Credit Agreement, \$611.0 million is available to borrow without adding additional properties to the unencumbered borrowing base of assets.

On January 7, 2016, the Operating Partnership issued and sold \$150.0 million aggregate principal amount of senior notes, comprised of (i) \$15.0 million aggregate principal amount of 4.03% Senior Notes, Series A, due January 7, 2023, (ii) \$45.0 million aggregate principal amount of 4.43% Senior Notes, Series B, due January 7, 2026, (iii) \$45.0 million aggregate principal amount of 4.57% Senior Notes, Series C, due January 7, 2028, and (iv) \$45.0 million aggregate principal amount of 4.74% Senior Notes, Series D, due January 7, 2031. On August 11, 2016, the note agreement for these notes was amended to make certain changes to its terms, including certain changes to affirmative covenants, negative covenants and definitions contained therein. Interest on each respective series of the January 2016 Senior Notes is payable semi-annually.

On August 11, 2016, the Operating Partnership issued and sold \$75.0 million aggregate principal amount of senior notes, comprised of (i) \$25.0 million aggregate principal amount of 4.09% Senior Notes, Series A, due August 11, 2025, (ii) \$25.0 million aggregate principal amount of 4.18% Senior Notes, Series B, due August 11, 2026, and (iii) \$25.0 million

Table of Contents

aggregate principal amount of 4.24% Senior Notes, Series C, due August 11, 2027. Interest on each respective series of the August 2016 Senior Notes is payable semi-annually.

On March 7, 2017, the Operating Partnership issued and sold \$400.0 million aggregate principal amount of 4.30% Senior Notes which will mature on March 15, 2027. The Senior Notes began accruing interest on March 7, 2017 and began paying interest semi-annually beginning September 15, 2017. The Senior Notes were sold at an issue price of 99.68% of their face value, before the underwriters' discount. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately \$396.1 million.

On December 1, 2017, the Operating Partnership issued and sold \$350.0 million aggregate principal amount of 3.95% Senior Notes which will mature on January 15, 2028. The Senior Notes began accruing interest on December 1, 2017 and will begin paying interest semi-annually beginning July 15, 2018. The Senior Notes were sold at an issue price of 99.78% of their face value, before the underwriters' discount. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately \$347.0 million.

Certain properties have mortgage debt that contains financial covenants. As of March 31, 2018, the Trust was in compliance with all mortgage debt financial covenants.

Scheduled principal payments due on debt as of March 31, 2018, are as follows (in thousands):

2018	\$22,618
2019	44,631
2020	252,121
2021	8,718
2022	24,708
Thereafter	1,248,726
Total Payments	\$1,601,522

As of March 31, 2018, the Company had total consolidated indebtedness of approximately \$1.6 billion. The weighted average interest rate on consolidated indebtedness was 3.84% (based on the 30-day LIBOR rate as of March 31, 2018, of 1.80%).

For the three month periods ended March 31, 2018 and 2017, the Company incurred interest expense on its debt, exclusive of deferred financing cost amortization, of \$16.0 million and \$9.3 million, respectively.

**Note 7. Derivatives**

In the normal course of business, a variety of financial instruments are used to manage or hedge interest rate risk. The Company has implemented ASC 815, *Derivatives and Hedging* (ASC 815), which establishes accounting and reporting standards requiring that all derivatives, including certain derivative instruments embedded in other contracts, be recorded as either an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sales exception.

When specific hedge accounting criteria are not met, ASC 815 requires that changes in a derivative's fair value be recognized currently in earnings. Changes in the fair market values of the Company's derivative instruments are recorded in the consolidated statements of income if such derivatives do not qualify for, or the Company does not elect to apply for, hedge accounting. If hedge accounting is applied to a derivative instrument, such changes are reported in accumulated other comprehensive income within the consolidated statement of equity, exclusive of ineffectiveness amounts, which are recognized as adjustments to net income.

To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of March 31, 2018, the Company had five outstanding interest rate swap contracts that are designated as cash flow hedges of interest rate risk. For presentational purposes, they are shown as one derivative due to the identical nature of their economic terms.



Table of Contents

The effective portion of the change in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income (“AOCI”) on the consolidated balance sheets and is subsequently reclassified into earnings as interest expense for the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. Hedge ineffectiveness was insignificant for the three months ended March 31, 2018. For the three months ended March 31, 2017 the Company recognized a \$0.2 million loss as a result of hedge ineffectiveness. The Company expects hedge ineffectiveness to be insignificant in the next 12 months.

The following table summarizes the location and aggregate fair value of the interest rate swaps on the Company’s consolidated balance sheets (in thousands):

Total notional amount	\$ 250,000
Effective fixed interest rate	(1)2.87 %
Effective date	7/7/2016
Maturity date	6/10/2023
Asset balance at March 31, 2018 (included in Other assets)	\$ 18,976
Asset balance at December 31, 2017 (included in Other assets)	\$ 14,693

(1) 1.07% effective swap rate plus 1.80% spread per Credit Agreement.

**Note 8. Accrued Expenses and Other Liabilities**

Accrued expenses and other liabilities consisted of the following as of March 31, 2018 and December 31, 2017 (in thousands):

	March 31, 2018	December 31, 2017
Prepaid rent	\$ 16,701	\$ 10,496
Real estate taxes payable	14,054	16,103
Accrued interest	7,711	11,107
Accrued expenses	4,590	8,751
Embedded derivative	3,776	—
Security deposits	2,810	2,882
Tenant improvement allowance	2,678	3,065
Accrued incentive compensation	860	1,625
Contingent consideration	803	1,454
Other	2,723	922
Total	\$ 56,706	\$ 56,405

**Note 9. Stock-based Compensation**

The Company follows ASC 718, *Compensation - Stock Compensation* (“ASC 718”), in accounting for its share-based payments. This guidance requires measurement of the cost of employee services received in exchange for stock compensation based on the grant-date fair value of the employee stock awards. This cost is recognized as compensation expense ratably over the employee’s requisite service period. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized when incurred. Share-based payments classified as liability awards are marked to fair value at each reporting period. Any common shares issued pursuant to the Company's incentive equity compensation and employee stock purchase plans will result in the Operating Partnership issuing OP Units to the Trust on a one-for-one basis, with the Operating Partnership receiving the net cash proceeds of such issuances.

Edgar Filing: Physicians Realty Trust - Form 10-Q

Certain of the Company's employee stock awards vest only upon the achievement of performance targets. ASC 718 requires recognition of compensation cost only when achievement of performance conditions is considered probable. Consequently, the Company's determination of the amount of stock compensation expense requires a significant level of judgment in estimating the probability of achievement of these performance targets. Subsequent changes in actual experience are monitored and estimates are updated as information is available.

Table of Contents

In connection with the IPO, the Trust adopted the 2013 Equity Incentive Plan (“2013 Plan”), which made available 600,000 common shares to be administered by the Compensation and Nominating Governance Committee of the Board of Trustees. On August 7, 2014, at the Annual Meeting of Shareholders of Physicians Realty Trust, the Trust’s shareholders approved an amendment to the 2013 Plan to increase the number of common shares authorized for issuance under the 2013 Plan by 1,850,000 common shares, for a total of 2,450,000 common shares authorized for issuance.

*Restricted Common Shares*

Restricted common shares granted under the 2013 Plan are eligible for dividends as well as the right to vote. In the three month period ended March 31, 2018, the Trust granted a total of 178,700 restricted common shares with a total value of \$2.6 million to its officers and certain of its employees, which have a vesting period of one year.

A summary of the status of the Trust’s non-vested restricted common shares as of March 31, 2018 and changes during the three month period then ended follow:

	Common Shares	Weighted Average Grant Date Fair Value
Non-vested at December 31, 2017	173,276	\$ 19.36
Granted	178,700	14.78
Vested	(133,052)	19.63
Non-vested at March 31, 2018	218,924	\$ 15.45

For all service awards, the Company records compensation expense for the entire award on a straight-line basis over the requisite service period. For the three month periods ended March 31, 2018 and 2017, the Company recognized non-cash share compensation of \$0.7 million and \$0.8 million, respectively. Unrecognized compensation expense at March 31, 2018 was \$2.9 million.

*Restricted Share Units*

In March 2018, under the 2013 Plan, the Trust granted restricted share units at a target level of 254,282 to its officers and certain employees and 50,745 to its trustees, which are subject to certain performance, timing, and market conditions and three-year and two-year service periods for officers/employees and trustees, respectively. In addition, each restricted share unit contains one dividend equivalent. The recipient will accrue dividend equivalents on awarded share units equal to the cash dividend that would have been paid on the awarded share unit had the awarded share unit been an issued and outstanding common share on the record date for the dividend.

Approximately 40% of the restricted share units issued to officers and certain employees vest based on certain market conditions. The market conditions were valued with the assistance of independent valuation specialists. The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair value of \$19.28 per unit for the March 2018 grant using the following assumptions:

Volatility	21.7	%
Dividend assumption	reinvested	
Expected term in years	2.8	years
Risk-free rate	2.40	%
Share price (per share)	\$ 14.78	

Edgar Filing: Physicians Realty Trust - Form 10-Q

The remaining 60% of the restricted share units issued to officers and certain employees, and 100% of restricted share units issued to trustees, vest based upon certain performance or timing conditions. With respect to the performance conditions of the March 2018 grant, the grant date fair value of \$14.78 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March 2018 restricted share units issued to officers and certain employees is \$16.58 per unit.

Table of Contents

The following is a summary of the activity in the Trust's restricted share units during the three months ended March 31, 2018:

	Executive Awards		Trustee Awards	
	Restricted Share Units	Weighted Average Grant Date Fair Value	Restricted Share Units	Weighted Average Grant Date Fair Value
Non-vested at December 31, 2017	354,123	\$ 26.30	51,220	\$ 19.04
Granted	254,282	16.58	50,745	14.78
Vested	(75,250 ) <sup>(1)</sup>	21.16	(34,807 )	18.67
Non-vested at March 31, 2018	533,155	\$ 22.66	67,158	\$ 16.01

<sup>(1)</sup> Restricted units vested by Company executives in 2018 resulted in the issuance of 126,108 common shares, less 56,502 common shares withheld to cover minimum withholding tax obligations, for multiple employees.

For the three month periods ending March 31, 2018 and 2017, the Trust recognized non-cash share restricted unit compensation expense of \$1.8 million and \$0.7 million, respectively. Unrecognized compensation expense at March 31, 2018 was \$8.5 million.

**Note 10. Fair Value Measurements**

ASC Topic 820, *Fair Value Measurement* ("ASC 820"), requires certain assets and liabilities be reported and/or disclosed at fair value in the financial statements and provides a framework for establishing that fair value. The framework for determining fair value is based on a hierarchy that prioritizes the valuation techniques and inputs used to measure fair value.

In general, fair values determined by Level 1 inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Fair values determined by Level 2 inputs use other inputs that are observable, either directly or indirectly. These Level 2 inputs include quoted prices for similar assets and liabilities in active markets, and other inputs such as interest rates and yield curves that are observable at commonly quoted intervals.

Level 3 inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset. These Level 3 fair value measurements are based primarily on management's own estimates using pricing models, discounted cash flow methodologies, or similar techniques taking into account the characteristics of the asset or liability. In instances where inputs used to measure fair value fall into different levels of the fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability.

The Company's derivative instruments as of March 31, 2018 consist of five interest rate swaps. For presentational purposes, the Company's interest rate swaps are shown as a single derivative due to the identical nature of their economic terms, as detailed in the Derivative Instruments section of Note 2 (Summary of Significant Accounting Policies) and Note 7 (Derivatives).

The Company's interest rate swaps are not traded on an exchange. The Company's derivative assets and liabilities are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis. The fair values are based on Level 2 inputs described above. The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivatives.

Edgar Filing: Physicians Realty Trust - Form 10-Q

The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. This generally includes assets subject to impairment. There were no such assets measured at fair value as of March 31, 2018.

The carrying amounts of cash and cash equivalents, tenant receivables, payables, and accrued interest are reasonable estimates of fair value because of the short term maturities of these instruments. Fair values for real estate loans receivable and mortgage debt are estimated based on rates currently prevailing for similar instruments of similar maturities and are based primarily on Level 2 inputs.

Table of Contents

As of March 31, 2018, the Company classified one portfolio, comprised of 15 properties, as held for sale. Upon classification as held for sale, we record the portfolio at the lower of its carrying amount or fair value, less costs to sell. Fair value is generally based on discounted cash flow analyses, which involved management's best estimate of market participants' holding period, market comparables, future occupancy levels, rental rates, capitalization rates, lease-up periods and capital requirements. As of March 31, 2018, fair value exceeds carrying value of our assets classified as held for sale and therefore, are recorded at respective carrying value.

The following table presents the fair value of the Company's financial instruments (in thousands):

	March 31, 2018		December 31, 2017	
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
Assets:				
Real estate loans receivable	\$71,529	\$70,587	\$76,195	\$75,288
Notes receivable	\$20,606	\$20,606	\$—	\$—
Derivative assets	\$18,976	\$18,976	\$14,693	\$14,693
Liabilities:				
Credit facility	\$(472,000)	\$(472,000)	\$(330,000)	\$(330,000)
Notes payable	\$(975,000)	\$(946,079)	\$(975,000)	\$(970,975)
Mortgage debt	\$(154,766)	\$(155,241)	\$(186,939)	\$(185,743)

**Note 11. Tenant Operating Leases**

The Company is lessor of medical office buildings and other healthcare facilities. Leases have expirations from 2018 through 2045. As of March 31, 2018, the future minimum rental payments on non-cancelable leases, exclusive of expense recoveries and 15 assets classified as held for sale, were as follows (in thousands):

2018	\$212,756
2019	283,265
2020	277,287
2021	270,694
2022	258,579
Thereafter	1,261,540
Total	\$2,564,121

**Note 12. Rent Expense**

The Company leases the rights to parking structures at two of its properties, the air space above one property, and the land upon which 77 of its properties are located from third party land owners pursuant to separate leases. In addition, the Company leases four individual office spaces.

The Company's leases require fixed rental payments and may also include escalation clauses and renewal options. These leases have terms of up to 87 years remaining, excluding extension options.

Table of Contents

As of March 31, 2018, the future minimum lease obligations under non-cancelable parking, air, ground, and office leases were as follows (in thousands):

2018	\$1,938
2019	2,577
2020	2,522
2021	2,537
2022	2,558
Thereafter	116,728
Total	\$128,860

Rent expense for the parking, air, and ground leases of \$0.6 million and \$0.6 million for the three month periods ended March 31, 2018 and 2017, respectively, are reported in operating expenses in the consolidated statements of income. Rent expense for office leases was insignificant for the three month periods ended March 31, 2018 and 2017, and is reported within general and administrative expenses in the consolidated statements of income.

**Note 13. Credit Concentration**

The Company uses annualized base rent (“ABR”) as its credit concentration metric. Annualized base rent is calculated by multiplying contractual base rent for the month ended March 31, 2018 by 12, excluding the impact of concessions and straight-line rent. The following table summarizes certain information about the Company’s top five tenant credit concentrations as of March 31, 2018, excluding assets classified as held for sale (in thousands):

Tenant	Total ABR	Percent of ABR
CHI - Nebraska	\$15,959	5.6 %
CHI - KentuckyOne Health	13,122	4.6 %
Baylor Scott and White Health	7,583	2.7 %
US Oncology	6,706	2.4 %
Northside Hospital (GA)	6,363	2.3 %
Remaining portfolio	232,409	82.4 %
Total	\$282,142	100.0 %

Annualized base rent collected from the Company’s top five tenant relationships comprises 17.6% of its total annualized base rent for the period ending March 31, 2018. Total annualized base rent from CHI affiliated tenants totals 18.9%, including the affiliates disclosed above. Consolidated financial statements of CHI, the parent of the subsidiaries and affiliates of the entities party to master lease agreements, are publicly available on the Catholic Health Initiatives website ([www.catholichealthinitiatvies.org/](http://www.catholichealthinitiatvies.org/)). Information included on the CHI website is not incorporated by reference within this Quarterly Report on Form 10-Q.

The following table summarizes certain information about the Company’s top five geographic concentrations as of March 31, 2018, excluding 15 assets classified as held for sale (in thousands):

State	Total ABR	Percent of ABR
Texas	\$47,121	16.7 %
Georgia	21,909	7.8 %
Indiana	18,103	6.4 %
Nebraska	17,361	6.2 %
Minnesota	16,706	5.9 %
Other	160,942	57.0 %



Edgar Filing: Physicians Realty Trust - Form 10-Q

Total \$282,142 100.0%

32

---

Table of Contents**Note 14. Earnings Per Share and Earnings Per Unit**

The following table shows the amounts used in computing the Trust's basic and diluted earnings per share (in thousands, except share and per share data):

	<b>Three Months Ended March 31,</b>	
	<b>2018</b>	<b>2017</b>
<b>Numerator for earnings per share - basic:</b>		
Net income	\$11,332	\$ 6,716
Net income attributable to noncontrolling interests:		
Operating Partnership	(313 )	(147 )
Partially owned properties	(111 )	(167 )
Preferred distributions	(487 )	(211 )
Numerator for earnings per share - basic	\$10,421	\$ 6,191
<b>Numerator for earnings per share - diluted:</b>		
Numerator for earnings per share - basic	\$10,421	\$ 6,191
Operating Partnership net income	313	147
Numerator for earnings per share - diluted	\$10,734	\$ 6,338
<b>Denominator for earnings per share - basic and diluted:</b>		
Weighted average number of shares outstanding - basic	181,809,570	188,986,629
Effect of dilutive securities:		
Noncontrolling interest - Operating Partnership units	5,454,494	3,186,117
Restricted common shares	53,179	96,643
Restricted share units	—	336,541
<b>Denominator for earnings per share - diluted:</b>	<b>187,317,243</b>	<b>192,605,930</b>
<b>Earnings per share - basic</b>	<b>\$0.06</b>	<b>\$ 0.04</b>
<b>Earnings per share - diluted</b>	<b>\$0.06</b>	<b>\$ 0.04</b>

For the three months ended March 31, 2018, total restricted share units of 600,313 were excluded from the computation of diluted earnings per share and diluted earnings per unit as their impact would have been anti-dilutive.

The following table shows the amounts used in computing the Operating Partnership's basic and diluted earnings per unit (in thousands, except unit and per unit data):

	<b>Three Months Ended March 31,</b>	
	<b>2018</b>	<b>2017</b>
<b>Numerator for earnings per unit - basic and diluted:</b>		
Net income	\$11,332	\$ 6,716
Net income attributable to noncontrolling interests - partially owned properties	(111 )	(167 )
Preferred distributions	(487 )	(211 )
Numerator for earnings per unit - basic and diluted	\$10,734	\$ 6,338
<b>Denominator for earnings per unit - basic and diluted:</b>		
Weighted average number of units outstanding - basic	187,264,064	192,172,746
Effect of dilutive securities:		
Restricted common shares	53,179	96,643
Restricted share units	—	336,541
<b>Denominator for earnings per unit - diluted</b>	<b>187,317,243</b>	<b>192,605,930</b>
<b>Earnings per unit - basic</b>	<b>\$0.06</b>	<b>\$ 0.04</b>
<b>Earnings per unit - diluted</b>	<b>\$0.06</b>	<b>\$ 0.04</b>



Table of Contents

**Note 15. Subsequent Events**

On April 3, 2018, the Trust, through a subsidiary of its Operating Partnership, closed on the acquisition of a medical office facility in Kingsport, Tennessee for approximately \$71.3 million.

Table of Contents

**Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion should be read in conjunction with our unaudited consolidated financial statements, including the notes to those statements, included in Part I, Item 1 of this report, and the Section entitled “Cautionary Statement Regarding Forward-Looking Statements” in this report. As discussed in more detail in the Section entitled “Cautionary Statement Regarding Forward-Looking Statements,” this discussion contains forward-looking statements, which involve risks and uncertainties. Our actual results may differ materially from the results discussed in the forward-looking statements. Factors that might cause those differences include those discussed in Part II, Item 1A (Risk Factors) of this report, and Part I, Item A (Business), and Part I, Item 1A (Risk Factors) of our 2017 Annual Report.*

**Overview**

We are a self-managed healthcare real estate company organized in April 2013 to acquire, selectively develop, own, and manage healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems. We invest in real estate that is integral to providing high quality healthcare services. Our properties are typically located on a campus with a hospital or other healthcare facilities or strategically located and affiliated with a hospital or other healthcare facilities. We believe the impact of government programs and continuing trends in the healthcare industry create attractive opportunities for us to invest in healthcare related real estate. In particular, we believe the demand for healthcare will continue to increase as a result of the aging population as older persons generally utilize healthcare services at a rate well in excess of younger people. Our management team has significant public healthcare REIT experience and has long established relationships with physicians, hospitals, and healthcare delivery system decision makers that we believe will provide quality investment and growth opportunities. Our principal investments include medical office buildings, outpatient treatment facilities, acute and post-acute care hospitals, as well as other real estate integral to health care providers. We seek to invest in stabilized medical facility assets with initial cash yields of 5.0% to 9.0%, although we invested in certain medical facility assets in 2017 with anticipated initial cash yields below 5.0% and we may invest in other medical facility assets with initial cash yields outside of this range. We seek to generate attractive risk-adjusted returns for our shareholders through a combination of stable and increasing dividends and potential long-term appreciation in the value of our properties and our common shares.

We have grown our portfolio of gross real estate investments from approximately \$124 million at the time of our IPO in July 2013 to approximately \$4.4 billion as of March 31, 2018. Since the date of our IPO through to March 31, 2018, our compounded annual growth rate was 115%. While we expect to continue to grow through property acquisitions and investments as our asset base continues to increase, we expect our annual growth rate to decelerate in the future.

As of March 31, 2018, our portfolio consisted of 265 healthcare properties (which excludes one portfolio comprised of 15 assets, representing approximately 560,234 leasable square feet in three states, classified as held for sale) located in 31 states with approximately 13,625,726 net leasable square feet, which were approximately 96.6% leased with a weighted average remaining lease term of approximately 8.2 years. As of March 31, 2018, approximately 85.0% of the net leasable square footage of our portfolio was either on campus with a hospital or other healthcare facility or strategically located and affiliated with a hospital or other healthcare facility.

We receive a cash rental stream from these healthcare providers under our leases. Approximately 92.2% of the annualized base rent payments from our properties as of March 31, 2018 are from triple-net leases, less assets held for sale, pursuant to which the tenants are responsible for all operating expenses relating to the property, including but not limited to real estate taxes, utilities, property insurance, routine maintenance and repairs, and property management. This structure helps insulate us from increases in certain operating expenses and provides more predictable cash flow. Approximately 6.3% of the annualized base rent payments from our properties as of March 31, 2018 are from modified gross base stop leases which allow us to pass through certain increases in future operating expenses (e.g.,

property tax and insurance) to tenants for reimbursement, thus protecting us from increases in such operating expenses.

We seek to structure our triple-net leases to generate attractive returns on a long-term basis. Our leases typically have initial terms of 5 to 15 years and include annual rent escalators of approximately 1.5% to 3.0%. Our operating results depend significantly upon the ability of our tenants to make required rental payments. We believe that our portfolio of medical office buildings and other healthcare facilities will enable us to generate stable cash flows over time because of the diversity of our tenants, staggered lease expiration schedule, long-term leases, and low historical occurrence of tenants defaulting under their leases. As of March 31, 2018, leases representing 1.9%, 3.8%, and 3.6% of leasable square feet in our portfolio will expire in 2018, 2019, and 2020, respectively.

We intend to grow our portfolio of high-quality healthcare properties leased to physicians, hospitals, healthcare delivery systems and other healthcare providers primarily through acquisitions of existing healthcare facilities that provide

## Table of Contents

stable revenue growth and predictable long-term cash flows. We may also selectively finance the development of new healthcare facilities through joint venture or fee arrangements with premier healthcare real estate developers. Generally, we only expect to make investments in new development properties when approximately 70% or more of the development property has been pre-leased before construction commences. We seek to invest in properties where we can develop strategic alliances with financially sound healthcare providers and healthcare delivery systems that offer need-based healthcare services in sustainable healthcare markets. We focus our investment activity on the following types of healthcare properties:

- medical office buildings;
- outpatient treatment and diagnostic facilities;
- physician group practice clinics;
- ambulatory surgery centers; and
- specialty hospitals and treatment centers.

We believe that shifting consumer preferences, limited space in hospitals, the desire of patients and healthcare providers to limit non-essential services provided in a hospital setting, and cost considerations, among other trends, continue to drive the industry trend of performing procedures in outpatient facilities that have traditionally been performed in hospitals, such as surgeries and other invasive medical procedures. As these trends continue, we believe that demand for medical office buildings and similar healthcare properties will continue to rise, and that our investment strategy accounts for these trends.

We may invest opportunistically in life science facilities, assisted living, and independent senior living facilities and in the longer term, senior housing properties, including skilled nursing. Consistent with our qualification as a REIT, we may also opportunistically invest in companies that provide healthcare services, and in joint venture entities with operating partners, structured to comply with the REIT Investment Diversification Act of 2007 (“RIDEA”).

One of the factors that influences the market price of our common shares is the dividend yield on common shares (as a percentage of the price of our common shares) relative to market interest rates. In response to the global financial crisis, the U.S. Federal Reserve took actions which resulted in low interest rates prevailing in the marketplace for a historically long period of time. Since December 2015, the U.S. Federal Reserve has raised its benchmark interest rate by a quarter of a percentage point six times to a range of 1.50% to 1.75% and is projected to raise its benchmark interest rate a couple more times in 2018. Further increases in market interest rates may lead prospective purchasers of our common shares to expect a higher dividend yield (with a resulting decline in the market price of our common shares) and higher interest rates would likely increase our borrowing costs for both our existing and future indebtedness and potentially decrease funds available for distribution. Thus, higher market interest rates could cause the market price of our common shares to decrease.

The Trust is a Maryland real estate investment trust and elected to be taxed as a REIT for U.S. federal income tax purposes. We conduct our business through an UPREIT structure in which our properties are owned by our Operating Partnership directly or through limited partnerships, limited liability companies or other subsidiaries. The Trust is the sole general partner of our Operating Partnership and, as of March 31, 2018, owned approximately 97.1% of the OP Units. As of April 30, 2018, there were 182,004,287 common shares outstanding.

## **Key Transactions in First Quarter 2018**

### *Investment Activity*

## Edgar Filing: Physicians Realty Trust - Form 10-Q

During the three months ended March 31, 2018, we completed acquisitions of 2 operating healthcare properties and 1 land parcel located in 3 states with approximately 220,140 net leasable square feet for an aggregate purchase price of approximately \$99.4 million. In addition, we completed a noncontrolling interest buyout for \$6.4 million and a \$2.0 million loan transaction, resulting in total investment activity of approximately \$107.8 million. Acquisitions are detailed in Note 3 (Acquisitions and Dispositions) to our consolidated financial statements included in Part I, Item 1 of this report.

### *Disposition Activity*

Since January 1, 2018, the Trust sold two medical office buildings, representing an aggregate 29,733 square feet, in Michigan and Florida for approximately \$2.5 million and recognized a net gain on the sale of approximately \$0.1 million.



## Table of Contents

### **Assets Slated for Disposition**

We consider 23 properties in six states, representing an aggregate of approximately 921,515 square feet of gross leasable area, to be slated for disposition as of March 31, 2018. These assets consist of one portfolio comprised of 15 assets representing approximately 560,234 leasable square feet in three states classified as held for sale, five assets affiliated with Foundation Healthcare, Inc. (OTC: FDNH) (“Foundation Healthcare”), and three additional properties which we believe no longer meet our core business strategy from a size, age, geography or line of business perspective.

### **Recent Developments**

#### *Quarterly Distribution*

On March 23, 2018, we announced that our Board of Trustees authorized and declared a cash distribution of \$0.23 per common share for the quarterly period ended March 31, 2018. The distribution was paid on April 18, 2018 to common shareholders and OP Unit holders of record as of the close of business on April 3, 2018.

#### *Investment Activity*

Since March 31, 2018, the Trust, through subsidiaries of its Operating Partnership, completed the acquisition of one healthcare property with approximately 231,486 net leasable square feet for an aggregate purchase price of approximately \$71.3 million.

### **Components of Our Revenues, Expenses, and Cash Flow**

#### ***Revenues***

Revenues consist primarily of the rental revenues and property operating expense recoveries we collect from tenants pursuant to our leases. Additionally, we recognize certain cash and non-cash revenues. These cash and non-cash revenues are highlighted below.

*Rental revenues.* Rental revenues represent rent under existing leases that is paid by our tenants, straight-lining of contractual rents and below-market lease amortization reduced by lease inducements and above-market lease amortization.

*Expense recoveries.* Certain of our leases require our tenants to make estimated payments to us to cover their proportional share of operating expenses, including but not limited to real estate taxes, property insurance, routine maintenance and repairs, utilities, and property management expenses. We collect these estimated expenses and are reimbursed by our tenants for any actual expenses in excess of our estimates or reimburse tenants if our collected estimates exceed our actual operating expenses. The net reimbursed operating expenses are included in revenues as expense recoveries.

We have certain tenants with absolute net leases. Under these lease agreements, the tenant is responsible for operating and building expenses. For absolute net leases, we do not recognize operating expense or expense recoveries.

*Interest income on real estate loans and other.* Represents interest income on mezzanine loans, term loans, notes receivable, income generated on tenant improvements, changes in the fair value of derivative instruments, and other. Interest income on the loans are recognized as earned based on the terms of the loans subject to evaluation of collectability risks.

***Expenses***

Expenses consist primarily of interest expense, general and administrative costs associated with operating our properties, operating expenses of our properties, depreciation and amortization, and prior to adoption of ASU 2017-01, costs we incur to acquire properties.

*Interest expense.* We recognize the interest expense we incur on our borrowings as interest expense. Additionally, we incur amortization expense for charges such as legal fees, commitment fees, and arrangement fees that reflect costs incurred with arranging certain debt financings. We generally recognize these costs over the term of the respective debt instrument for which the costs were incurred as a component of interest expense.

*General and administrative.* General and administrative expenses include certain expenses such as compensation, accounting, legal, and other professional fees as well as certain other administrative and travel costs, and expenses related to

Table of Contents

bank charges, franchise taxes, corporate filing fees, exchange listing fees, officer and trustee insurance costs, and other costs associated with being a public company.

*Operating Expenses.* Operating expenses include property operating expenses such as real estate taxes, property insurance, routine maintenance and repairs, utilities, and third party property management expenses, some of which are reimbursed to us by tenants under the terms of triple net and modified gross base stop leases.

*Depreciation and amortization.* We incur depreciation and amortization expense on all of our long-lived assets. This non-cash expense is designed under generally accepted accounting principles, or GAAP, to reflect the economic useful lives of our assets.

*Acquisition expenses.* Acquisition costs are costs we incur in pursuing and closing property acquisitions accounted for as business combinations. These costs include legal, accounting, valuation, other professional or consulting fees, and the compensation of certain employees who dedicate substantially all of their time to acquisition related job functions. We account for acquisition-related costs as expenses in the period in which the costs are incurred and the services are received.

*Equity in income of unconsolidated entities.* We recognize our share of earnings and losses from unconsolidated joint venture investments in Louisiana.

**Cash Flow**

*Cash flows from operating activities.* Cash flows from operating activities are derived largely from net income by adjusting our revenues for those amounts not collected in cash during the period in which the revenue is recognized and for cash collected that was billed in prior periods or will be billed in future periods. Net income is further adjusted by adding back expenses charged in the period that are not paid for in cash during the same period. We expect to make our distributions based largely from cash provided by operations.

*Cash flows from investing activities.* Cash flows from investing activities consist of cash that is used during a period for making new investments and capital expenditures, offset by cash provided from sales of real estate investments.

*Cash flows from financing activities.* Cash flows from financing activities consist of cash we receive from debt and equity financings. This cash provides the primary basis for investments in new properties and capital expenditures. While we may invest a portion of our cash from operations into new investments, as a result of the distribution requirements to maintain our REIT status, it is likely that additional debt or equity financings will finance the majority of our investment activity. Cash used in financing activities consists of repayment of debt and distributions paid to shareholders and OP Unit holders.

Table of Contents**Results of Operations***Three Months Ended March 31, 2018 compared to the three months ended March 31, 2017.*

The following table summarizes our results of operations for the three months ended March 31, 2018 and 2017 (in thousands):

	2018	2017	Change	%	
<b>Revenues:</b>					
Rental revenues	\$78,887	\$59,092	\$19,795	33.5	%
Expense recoveries	24,308	16,354	7,954	48.6	%
Interest income on real estate loans and other	2,028	1,220	808	66.2	%
Total revenues	105,223	76,666	28,557	37.2	%
<b>Expenses:</b>					
Interest expense	16,494	9,815	6,679	68.0	%
General and administrative	8,459	4,736	3,723	78.6	%
Operating expenses	30,459	22,089	8,370	37.9	%
Depreciation and amortization	38,576	27,933	10,643	38.1	%
Acquisition expenses	—	5,405	(5,405)	(100.0)	%
Total expenses	93,988	69,978	24,010	34.3	%
<b>Income before equity in income of unconsolidated entities and gain on sale of investment properties:</b>	11,235	6,688	4,547	68.0	%
Equity in income of unconsolidated entities	28	28	—	—	%
Gain on sale of investment properties	69	—	69	NM	
Net income	\$11,332	\$6,716	\$4,616	68.7	%

NM = Not Meaningful

**Revenues**

Total revenues increased \$28.6 million, or 37.2%, for the three months ended March 31, 2018 as compared to the three months ended March 31, 2017. An analysis of selected revenues follows.

*Rental revenues.* Rental revenues increased \$19.8 million, or 33.5%, from \$59.1 million for the three months ended March 31, 2017 to \$78.9 million for the three months ended March 31, 2018. The increase in rental revenues primarily resulted from our 2018 and 2017 acquisitions in the last twelve months which resulted in additional rental revenue of \$1.4 million and \$19.4 million, respectively. Revenues were partially offset by decline in rental income recognized at the Kennewick medical office building located in Kennewick, Washington (the “Kennewick MOB”) of \$1.3 million.

*Expense recoveries.* Expense recoveries increased \$8.0 million, or 48.6%, for the three months ended March 31, 2018 as compared to the three months ended March 31, 2017. The increase in expense recoveries primarily resulted from our 2018 and 2017 acquisitions which resulted in additional expense recoveries of \$0.5 million and \$7.2 million, respectively.

*Interest income on real estate loans and other.* Interest income on real estate loans and other increased \$0.8 million, or 66.2%, for the three months ended March 31, 2018 as compared to the three months ended March 31, 2017. The increase is attributable to \$0.5 million of interest earned on the Company’s outstanding real estate loans receivable and deposit accounts and \$0.3 million of income from tenant improvements build outs in excess of allowance given.

**Expenses**

Edgar Filing: Physicians Realty Trust - Form 10-Q

Total expenses increased by \$24.0 million, or 34.3%, for the three months ended March 31, 2018 as compared to the three months ended March 31, 2017. An analysis of selected expenses follows.

*Interest expense.* Interest expense for the three months ended March 31, 2018 was \$16.5 million compared to \$9.8 million for the three months ended March 31, 2017, representing an increase of \$6.7 million, or 68.0%. The increase is primarily related to our March 2017 and December 2017 public debt offerings.

Table of Contents

*General and administrative.* General and administrative expenses increased \$3.7 million or 78.6%, from \$4.7 million during the three months ended March 31, 2017 to \$8.5 million during the three months ended March 31, 2018. The increase is partially attributable to the adoption of ASU 2017-01, which resulted in the addition of approximately \$0.4 million cash acquisition pursuit costs and \$0.5 million non-cash acquisition pursuit costs that would have previously been classified as acquisition expenses. The increase is also attributed to increased non-cash share compensation of \$1.1 million, increased employee salaries and benefits of \$0.6 million, increased office expenditures of \$0.5 million, increased professional fees of \$0.4 million, and increased travel expenditures of \$0.2 million.

*Operating expenses.* Operating expenses increased \$8.4 million or 37.9%, from \$22.1 million during the three months ended March 31, 2017 to \$30.5 million during the three months ended March 31, 2018. The increase is primarily due to our 2018 and 2017 property acquisitions which resulted in additional operating expenses of \$0.5 million and \$7.9 million, respectively.

*Depreciation and amortization.* Depreciation and amortization increased \$10.6 million, or 38.1%, from \$27.9 million during the three months ended March 31, 2017 to \$38.6 million during the three months ended March 31, 2018. The increase is primarily due to our 2018 and 2017 property acquisitions which resulted in additional depreciation and amortization of \$0.9 million and \$11.3 million, respectively, partially offset by a reduction in depreciation and amortization associated with prior period acquisitions, which included a reduction of \$1.2 million from in-place leases that were either terminated early or fully depreciated in 2017.

*Acquisition expenses.* During the first quarter of 2018, the Company adopted ASU 2017-01 which clarifies the framework for determining whether an integrated set of assets and activities meets the definition of a business. The Company determined that all 2018 acquisitions of real estate, or in-substance real estate, has not met the revised definition of a business. As such, acquisition pursuit costs are capitalized in accordance with the new guidance and there is no acquisition expense for three months ended March 31, 2018.

*Equity in income of unconsolidated entities.* The change in equity income from unconsolidated entities for the three months ended March 31, 2018 compared to the three months ended March 31, 2017 is not significant.

*Gain on sale of properties.* During the three months ended March 31, 2018, the Trust sold two properties with 29,733 net leasable square feet located in Michigan and Florida for approximately \$2.5 million, realizing a gain of \$0.1 million. We did not dispose of any properties during the three months ended March 31, 2017.

**Cash Flows*****Three months ended March 31, 2018 compared to the three months ended March 31, 2017.***

	2018	2017
Cash provided by operating activities	\$40,890	\$33,886
Cash used in investing activities	(106,422)	(163,747 )
Cash provided by financing activities	69,355	231,854
Increase in cash and cash equivalents	\$3,823	\$101,993

*Cash flows from operating activities.* Cash flows provided by operating activities was \$40.9 million during the three months ended March 31, 2018 compared to \$33.9 million during the three months ended March 31, 2017, representing an increase of \$7.0 million. This change is attributable to the increased operating cash flows resulting from our 2018 and 2017 acquisitions.

*Cash flows from investing activities.* Cash flows used in investing activities was \$106.4 million during the three months ended March 31, 2018 compared to cash flows used in investing activities of \$163.7 million during the three

months ended March 31, 2017, representing a change of \$57.3 million. The decrease in cash flows used in investing activities was primarily attributable to our decrease in cash spent on acquisitions over the prior period.

*Cash flows from financing activities.* Cash flows provided by financing activities was \$69.4 million during the three months ended March 31, 2018 compared to cash flows provided by financing activities of \$231.9 million during the three months ended March 31, 2017, representing a decrease of \$162.5 million. The 2018 activity was primarily attributable to \$166.0 million of proceeds from the credit facility. These were partially offset by \$32.2 million of payments on mortgage debt, \$24.0 million of repayments on our revolving credit facility, and \$42.3 million of dividends paid.

Table of Contents**Non-GAAP Financial Measures**

This report includes Funds From Operations (FFO), Normalized FFO, Normalized Funds Available For Distribution (FAD), Net Operating Income (NOI), Cash NOI, Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate (EBITDA<sub>re</sub>) and Adjusted EBITDA<sub>re</sub>, which are non-GAAP financial measures. For purposes of Item 10(e) of Regulation S-K promulgated under the Securities Act, a non-GAAP financial measure is a numerical measure of a company's historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable financial measure calculated and presented in accordance with GAAP in the statement of operations, balance sheet or statement of cash flows (or equivalent statements) of the company, or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable financial measure so calculated and presented. As used in this report, GAAP refers to generally accepted accounting principles in the United States of America. Pursuant to the requirements of Item 10(e) of Regulation S-K promulgated under the Securities Act, we have provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

***Funds From Operations (FFO) and Normalized FFO***

We believe that information regarding FFO is helpful to shareholders and potential investors because it facilitates an understanding of the operating performance of our properties without giving effect to real estate depreciation and amortization, which assumes that the value of real estate assets diminishes ratably over time. We calculate FFO in accordance with standards established by the National Association of Real Estate Investment Trusts ("NAREIT"). NAREIT defines FFO as net income or loss (computed in accordance with GAAP) before noncontrolling interests of holders of OP units, excluding preferred distributions, gains (or losses) on sales of depreciable operating property, impairment write-downs on depreciable assets, plus real estate related depreciation and amortization (excluding amortization of deferred financing costs). Our FFO computation may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with NAREIT definition or that interpret the NAREIT definition differently than we do. The GAAP measure that we believe to be most directly comparable to FFO, net income, includes depreciation and amortization expenses, gains or losses on property sales, impairments and noncontrolling interests. In computing FFO, we eliminate these items because, in our view, they are not indicative of the results from the operations of our properties. To facilitate a clear understanding of our historical operating results, FFO should be examined in conjunction with net income (determined in accordance with GAAP) as presented in our financial statements. FFO does not represent cash generated from operating activities in accordance with GAAP, should not be considered to be an alternative to net income or loss (determined in accordance with GAAP) as a measure of our liquidity and is not indicative of funds available for our cash needs, including our ability to make cash distributions to shareholders.

We use Normalized FFO, which excludes from FFO net change in fair value of derivative financial instruments, acquisition expenses, acceleration of deferred financing costs, change in fair value of contingent consideration, and other normalizing items. However, our use of the term Normalized FFO may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount. Normalized FFO should not be considered as an alternative to net income or loss (computed in accordance with GAAP), as an indicator of our financial performance or of cash flow from operating activities (computed in accordance with GAAP), or as an indicator of our liquidity, nor is it indicative of funds available to fund our cash needs, including its ability to make distributions. Normalized FFO should be reviewed in connection with other GAAP measurements.



Table of Contents

The following is a reconciliation from net income, the most direct financial measure calculated and presented in accordance with GAAP, to FFO and Normalized FFO (in thousands, except per share data):

	Three Months Ended	
	March 31,	
	2018	2017
Net income	\$ 11,332	\$ 6,716
Earnings per share - diluted	\$0.06	\$ 0.04
Net income	\$ 11,332	\$ 6,716
Net income attributable to noncontrolling interests - partially owned properties	(111 )	(167 )
Preferred distributions	(487 )	(211 )
Depreciation and amortization expense	38,530	27,911
Depreciation and amortization expense - partially owned properties	(166 )	(152 )
Gain on the sale of investment properties	(69 )	—
FFO applicable to common shares and OP Units	\$49,029	\$ 34,097
FFO per common share and OP Unit	\$0.26	\$ 0.24
Net change in fair value of derivative	2	165
Acquisition expenses	—	5,405
Net change in fair value of contingent consideration	—	(70 )
Normalized FFO applicable to common shares and OP Units	\$49,031	\$ 39,597
Normalized FFO per common share and OP Unit	\$0.26	\$ 0.28
Weighted average number of common shares and OP Units outstanding	187,317,243	182,605,930

***Normalized Funds Available for Distribution (FAD)***

We define Normalized FAD, a non-GAAP measure, which excludes from Normalized FFO non-cash share compensation expense, straight-line rent adjustments, amortization of acquired above- or below-market leases and assumed debt, amortization of lease inducements, amortization of deferred financing costs, and recurring capital expenditures related to tenant improvements and leasing commissions, and includes cash payments from seller master leases and rent abatement payments. Other REITs or real estate companies may use different methodologies for calculating Normalized FAD, and accordingly, our computation may not be comparable to those reported by other REITs. Although our computation of Normalized FAD may not be comparable to that of other REITs, we believe Normalized FAD provides a meaningful supplemental measure of our performance due to its frequency of use by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. Normalized FAD should not be considered as an alternative to net income or loss attributable to controlling interest (computed in accordance with GAAP) or as an indicator of our financial performance. Normalized FAD should be reviewed in connection with other GAAP measurements.

Table of Contents

The following is a reconciliation from net income, the most direct financial measure calculated and presented in accordance with GAAP, to Normalized FAD (in thousands):

	<b>Three Months Ended</b>	
	<b>March 31,</b>	
	<b>2018</b>	<b>2017</b>
Net income	\$ 11,332	\$ 6,716
Normalized FFO applicable to common shares and OP Units	\$ 49,031	\$ 39,597
Normalized FFO applicable to common shares and OP Units	\$ 49,031	\$ 39,597
Non-cash share compensation expense	2,605	1,066
Straight-line rent adjustments	(6,450 )	(4,508 )
Amortization of acquired above/below-market leases/assumed debt	830	938
Amortization of lease inducements	344	310
Amortization of deferred financing costs	618	549
TI/LC and recurring capital expenditures	(4,158 )	(3,213 )
Seller master lease and rent abatement payments	229	254
Normalized FAD applicable to common shares and OP Units	\$ 43,049	\$ 34,993

***Net Operating Income (NOI) and Cash NOI***

NOI is a non-GAAP financial measure that is defined as net income or loss, computed in accordance with GAAP, generated from our total portfolio of properties before general and administrative expenses, acquisition-related expenses, depreciation and amortization expense, interest expense, net change in the fair value of derivative financial instruments, gain or loss on the sale of investment properties, and impairment losses. We believe that NOI provides an accurate measure of operating performance of our operating assets because NOI excludes certain items that are not associated with management of the properties. Our use of the term NOI may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount.

Cash NOI is a non-GAAP financial measure which excludes from NOI straight-line rent adjustments, amortization of acquired above and below market leases, and other non-cash and normalizing items. Other non-cash and normalizing items include items such as the amortization of lease inducements, payments received from seller master leases and rent abatements, and changes in fair value of contingent consideration. We believe that Cash NOI provides an accurate measure of the operating performance of our operating assets because it excludes certain items that are not associated with management of the properties. Additionally, we believe that Cash NOI is a widely accepted measure of comparative operating performance in the real estate community. Our use of the term Cash NOI may not be comparable to that of other real estate companies as such other companies may have different methodologies for computing this amount.

Table of Contents

The following is a reconciliation from the Trust's net income, the most direct financial measure calculated and presented in accordance with GAAP, to NOI and Cash NOI (in thousands):

	Three Months Ended	
	March 31,	
	2018	2017
Net income	\$ 11,332	\$ 6,716
General and administrative	8,459	4,736
Acquisition expenses	—	5,405
Depreciation and amortization	38,576	27,933
Interest expense	16,494	9,815
Net change in the fair value of derivative	2	165
Gain on sale of investment properties	(69 )	—
NOI	\$ 74,794	\$ 54,770
NOI	\$ 74,794	\$ 54,770
Straight-line rent adjustments	(6,450 )	(4,508 )
Amortization of acquired above/below-market leases/assumed debt	830	938
Amortization of lease inducements	344	310
Seller master lease and rent abatement payments	229	254
Change in fair value of contingent consideration	—	(70 )
Cash NOI	\$ 69,747	\$ 51,694

***Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate (EBITDAre) and Adjusted EBITDAre***

We define *EBITDAre* as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, loss (gain) on dispositions, and impairment loss on depreciated property. We define *Adjusted EBITDAre* as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, loss (gain) on dispositions, impairment loss on depreciated property, acquisition expenses, non-cash share compensation expense, non-cash changes in fair value, and other normalizing items. We consider *EBITDAre* and *Adjusted EBITDAre* important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

The following is a reconciliation from the Trust's net income, the most direct financial measure calculated and presented in accordance with GAAP, to *EBITDAre* and *Adjusted EBITDAre* (in thousands):

	Three Months Ended	
	March 31,	
	2018	2017
Net income	\$ 11,332	\$ 6,716
Depreciation and amortization	38,576	27,933
Interest expense	16,494	9,815
Gain on sale of investment properties	(69 )	—
<i>EBITDAre</i>	\$ 66,333	\$ 44,464
Acquisition expenses	—	5,405
Non-cash share compensation expense	2,605	1,066
Non-cash changes in fair value	2	95
<i>Adjusted EBITDAre</i>	\$ 68,940	\$ 51,030



Table of Contents

**Liquidity and Capital Resources**

Our short-term liquidity requirements consist primarily of operating and interest expenses and other expenditures directly associated with our properties, including:

- property expenses;
- interest expense and scheduled principal payments on outstanding indebtedness;
- general and administrative expenses; and
- capital expenditures for tenant improvements and leasing commissions.

In addition, we will require funds for future distributions expected to be paid to our common shareholders and OP Unit holders in our Operating Partnership.

As of March 31, 2018, we had a total of \$6.6 million of cash and cash equivalents and \$611.0 million of near-term availability on our unsecured revolving credit facility. Our primary sources of cash include rent we collect from our tenants, borrowings under our unsecured credit facility, and financings of debt and equity securities. We believe that our existing cash and cash equivalents, cash flow from operating activities, and borrowings available under our unsecured revolving credit facility will be adequate to fund any existing contractual obligations to purchase properties and other obligations through the next twelve months. However, because of the 90% distribution requirement under the REIT tax rules under the Code, we may not be able to fund all of our future capital needs from cash retained from operations, including capital needed to make investments and to satisfy or refinance maturing obligations. As a result, we expect to rely upon external sources of capital, including debt and equity financing, to fund future capital needs. If we are unable to obtain needed capital on satisfactory terms or at all, we may not be able to make the investments needed to expand our business or to meet our obligations and commitments as they mature. We will rely upon external sources of capital to fund future capital needs, and, if we encounter difficulty in obtaining such capital, we may not be able to make future acquisitions necessary to grow our business or meet maturing obligations.

Our long-term liquidity needs consist primarily of funds necessary to pay for acquisitions, recurring and non-recurring capital expenditures and scheduled debt maturities. We expect to satisfy our long-term liquidity needs through cash flow from operations, unsecured borrowings, issuances of equity and debt securities, and, in connection with acquisitions of additional properties, the issuance of OP Units of our Operating Partnership, and proceeds from select property dispositions and joint venture transactions.

Our ability to access capital in a timely and cost-effective manner is essential to the success of our business strategy as it affects our ability to satisfy existing obligations, including repayment of maturing indebtedness, and to make future investments and acquisitions. Factors such as general market conditions, interest rates, credit ratings on our debt and equity securities, expectations of our potential future earnings and cash distributions, and the trading price of our common shares, each of which are beyond our control and vary or fluctuate over time, all impact our access to and cost of capital. In particular, to the extent interest rates continue to rise, we may experience a decline in the trading price of our common shares, which may impact our decision to conduct equity offerings for capital raising purposes. We will likely also experience higher borrowing costs as interest rates rise, which may also impact our decisions to incur additional indebtedness, or to engage in transactions for which we may need to fund through borrowing. We expect to continue to utilize equity and debt financings to support our future growth and investment activity.

We also continuously evaluate opportunities to finance future investments. New investments are generally funded from temporary borrowings under our primary unsecured credit facility and the proceeds from financing transactions such as those discussed above. Our investments generate cash from net operating income and principal payments on loans receivable. Permanent financing for future investments, which generally replaces funds drawn under our primary unsecured credit facility, has historically been provided through a combination of the issuance of debt and equity

securities and the incurrence or assumption of secured debt.

We intend to invest in additional properties as suitable opportunities arise and adequate sources of financing are available. We currently are evaluating additional potential investments consistent with the normal course of our business. There can be no assurance as to whether or when any portion of these investments will be completed. Our ability to complete investments is subject to a number of risks and variables, including our ability to negotiate mutually agreeable terms with sellers and our ability to finance the investment. We may not be successful in identifying and consummating suitable acquisitions or investment opportunities, which may impede our growth and negatively affect our results of operations and may result in the use of a significant amount of management resources. We expect that future investments in properties will depend

Table of Contents

on and will be financed by, in whole or in part, our existing cash, borrowings, including under our unsecured revolving credit facility or the proceeds from additional issuances of equity or debt securities.

While we intend to sell the 23 assets slated for disposition for other business reasons, we currently do not expect to sell any of our properties to meet our liquidity needs, although we may do so in the future.

We intend to refinance at maturity the mortgage notes payable that have balloon payments at maturity.

We currently are in compliance with all debt covenants on our outstanding indebtedness.

***Credit Facility***

On June 10, 2016, the Operating Partnership, as borrower, and the Trust entered into an amended and restated Credit Agreement with KeyBank National Association, as administrative agent, KeyBanc Capital Markets Inc., BMO Capital Markets, and Citizens Bank N.A., as joint lead arrangers and co-book runners, BMO Capital Markets and Citizens Bank N.A., as co-syndication agents, and the lenders party thereto (the "Credit Agreement") which increased the maximum principal amount available under an unsecured revolving credit facility from \$750 million to \$850 million. The Credit Agreement contains a 7-year term loan feature allowing us to borrow in a single drawing up to \$250 million, increasing the borrowing capacity to an aggregate \$1.1 billion. The Credit Agreement also includes a swingline loan commitment for up to 10% of the maximum principal amount and provides an accordion feature allowing us to increase borrowing capacity by up to an additional \$500 million, subject to customary terms and conditions, resulting in a maximum borrowing capacity of \$1.6 billion.

On July 7, 2016, the Operating Partnership borrowed \$250.0 million under the 7-year term loan feature of the Credit Agreement. Borrowings under the term loan feature of the Credit Agreement bear interest on the outstanding principal amount at a rate which is determined by the Trust's credit rating, currently equal to LIBOR + 1.80%. The Trust simultaneously entered into a pay-fixed receive-variable rate swap for the full borrowing amount, fixing the LIBOR component of the borrowing rate to 1.07%, for an all-in fixed rate of 2.87%. Both the borrowing and pay-fixed receive-variable swap have a maturity date of June 10, 2023.

The Credit Agreement has a maturity date of September 18, 2020 and includes a one year extension option. Borrowings under the Credit Agreement bear interest on the outstanding principal amount at an adjusted LIBOR rate, which is based on the Trust's investment grade rating under the Credit Agreement. As of March 31, 2018, the Trust had an investment grade rating of Baa3 from Moody's and BBB- from S&P. As such, borrowings under the revolving credit facility of the Credit Agreement accrued interest on the outstanding principal at a rate of LIBOR plus 1.20%. The Credit Agreement includes a facility fee equal to 0.25% per annum, which is also determined by the Trust's investment grade rating.

The Credit Agreement contains financial covenants that, among other things, require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as covenants that may limit our ability to incur additional debt or make distributions. We may, at any time, voluntarily prepay any revolving or swingline loan under the Credit Agreement in whole or in part without premium or penalty. Prepayments of term borrowings require payment of premiums of up to 2.0% of the amount of prepayment, dependent on date of such prepayment. As of March 31, 2018, we were in compliance with all financial covenants related to the Credit Agreement.

The Credit Agreement includes customary representations and warranties by us and imposes customary covenants on us. The Credit Agreement also contains customary events of default, and if an event of default occurs and continues, the Operating Partnership is subject to certain actions by the administrative agent, including without limitation, the acceleration of repayment of all amounts outstanding under the Credit Agreement.





Table of Contents

The Credit Agreement provides for revolving credit and term loans to the Operating Partnership. Base Rate Loans, Adjusted LIBOR Rate Loans, and Letters of Credit (each, as defined in the Credit Agreement) will be subject to interest rates, based upon the Trust's investment grade rating as follows:

Credit Rating	Margin for Revolving Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee	Margin for Revolving Loans: Base Rate Loans	Margin for Term Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee	Margin for Term Loans: Base Rate Loans
At Least A- or A3	LIBOR + 0.85%	— %	LIBOR + 1.40%	0.40 %
At Least BBB+ or Baa1	LIBOR + 0.90%	— %	LIBOR + 1.45%	0.45 %
At Least BBB or Baa2	LIBOR + 1.00%	0.10 %	LIBOR + 1.55%	0.55 %
At Least BBB- or Baa3	LIBOR + 1.20%	0.20 %	LIBOR + 1.80%	0.80 %
Below BBB- or Baa3	LIBOR + 1.55%	0.60 %	LIBOR + 2.25%	1.25 %

As of March 31, 2018, the company had \$222.0 million of borrowings outstanding under its unsecured revolving credit facility, and \$250.0 million of borrowings outstanding under the term loan feature of the Credit Agreement. The Company has also issued a letter of credit for \$17.0 million with no outstanding balance as of March 31, 2018. As defined by the Credit Agreement, \$611.0 million is available to borrow without adding additional properties to the unencumbered borrowing base of assets.

**Senior Notes**

On January 7, 2016, the Operating Partnership issued and sold \$150.0 million aggregate principal amount of senior notes, comprised of (i) \$15.0 million aggregate principal amount of 4.03% Senior Notes, Series A, due January 7, 2023, (ii) \$45.0 million aggregate principal amount of 4.43% Senior Notes, Series B, due January 7, 2026, (iii) \$45.0 million aggregate principal amount of 4.57% Senior Notes, Series C, due January 7, 2028, and (iv) \$45.0 million aggregate principal amount of 4.74% Senior Notes, Series D, due January 7, 2031. On August 11, 2016, the note agreement for these notes was amended to make certain changes to its terms, including certain changes to affirmative covenants, negative covenants and definitions contained therein. Interest on each respective series of the January 2016 Senior Notes is payable semi-annually. The proceeds of the Notes were used to repay borrowings under our unsecured revolving credit facility and for general corporate and working capital purposes and funding acquisitions.

On August 11, 2016, the Operating Partnership issued and sold \$75.0 million aggregate principal amount of senior notes, comprised of (i) \$25.0 million aggregate principal amount of 4.09% Senior Notes, Series A, due August 11, 2025, (ii) \$25.0 million aggregate principal amount of 4.18% Senior Notes, Series B, due August 11, 2026, and (iii) \$25.0 million aggregate principal amount of 4.24% Senior Notes, Series C, due August 11, 2027. Interest on each respective series of the August 2016 Senior Notes is payable semi-annually.

The note agreements covering the notes described above contain covenants that are substantially similar to those contained in the Credit Agreement, including financial covenants that require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as other affirmative and negative covenants that may limit, among other things, our ability to incur additional debt, make distributions or investments, incur liens and sell, transfer or dispose of assets. The note agreements also include customary representations and warranties and customary events of default substantially similar to those contained in the Credit Agreement.

## Edgar Filing: Physicians Realty Trust - Form 10-Q

On March 7, 2017, the Operating Partnership issued \$400.0 million in aggregate principal amount of its 4.30% Senior Notes due March 15, 2027 (the “2027 Senior Notes”) in a public offering (the “Debt Offering”) through underwriters for whom J.P. Morgan Securities LLC, Credit Agricole Securities (USA) Inc. and Jefferies LLC acted as representatives (the “Representatives”) pursuant to an underwriting agreement, dated March 2, 2017 (the “Underwriting Agreement”), among the Operating Partnership, the Trust and the Representatives. The Underwriting Agreement contains customary representations, warranties and agreements by the Operating Partnership and the Trust, customary conditions to closing, indemnification obligations of the Operating Partnership, the Trust and the underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions.

The 2027 Senior Notes were registered under the Securities Act on the Trust’s and the Operating Partnership’s automatic shelf registration statement on Form S-3ASR (File No. 333-216214), filed with the Commission on February 24, 2017.

The 2027 Senior Notes are the senior unsecured indebtedness of the Operating Partnership and rank equally in right of payment with all of the Operating Partnership’s existing and future senior unsecured indebtedness. As a result, the 2027 Senior

Table of Contents

Notes effectively are subordinated in right of payment to all of the Operating Partnership's existing and future secured indebtedness (to the extent of the value of the collateral securing such indebtedness), and all mortgages, preferred equity and indebtedness and other liabilities, whether secured or unsecured, of the Operating Partnership's subsidiaries. The Operating Partnership's obligations under the 2027 Senior Notes are fully and unconditionally guaranteed by the Trust.

The 2027 Senior Notes began accruing interest on March 7, 2017 and began paying interest semi-annually beginning September 15, 2017. The 2027 Senior Notes were sold at an issue price of 99.68% of their face value, before the underwriters' discount. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately \$396.1 million. We used the net proceeds of the Debt Offering to repay a portion of the outstanding indebtedness under our unsecured revolving credit facility and for general corporate purposes, including working capital and funding acquisitions.

The 2027 Senior Notes are subject to customary events of default, which may result in the accelerated maturity of the 2027 Senior Notes.

On December 1, 2017, the Operating Partnership issued \$350.0 million in aggregate principal amount of 3.95% Senior Notes due January 15, 2028 (the "2028 Senior Notes") in a public offering (the "December Debt Offering") through underwriters for whom J.P. Morgan Securities LLC, Credit Agricole Securities (USA) Inc., and Jefferies LLC acted as representatives (the "Representatives") pursuant to an underwriting agreement, dated November 28, 2017 (the "Underwriting Agreement"), among the Operating Partnership, the Trust, and the Representatives.

The 2028 Senior Notes were registered under the Securities Act on the Trust's and the Operating Partnership's automatic shelf registration statement on Form S-3ASR (File No. 333-216214), filed with the Commission on February 24, 2017.

The 2028 Senior Notes began accruing interest on December 1, 2017 and will begin paying interest semi-annually on July 15, 2018. The 2028 Senior Notes were sold at an issue price of 99.78% of their face value, before the underwriters' discount. The net proceeds of the Offering were approximately \$347.0 million, after deducting the underwriting discount and estimated offering expenses of the Trust and the Operating Partnership. We used the net proceeds of the December Debt Offering (i) to repay outstanding indebtedness under our unsecured revolving credit facility and (ii) for general corporate purposes, including, without limitation, working capital and investment in real estate.

The 2028 Senior Notes are subject to customary events of default, which may result in the accelerated maturity of the 2028 Senior Notes.

As of March 31, 2018, we had \$975.0 million aggregate principal amount of senior notes issued and outstanding by the Operating Partnership, as follows: (i) \$15.0 million aggregate principal amount of 4.03% Senior Notes, Series A, due January 7, 2023, (ii) \$45.0 million aggregate principal amount of 4.43% Senior Notes, Series B, due January 7, 2026, (iii) \$45.0 million aggregate principal amount of 4.57% Senior Notes, Series C, due January 7, 2028, (iv) \$45.0 million aggregate principal amount of 4.74% Senior Notes, Series D, due January 7, 2031, (v) \$25.0 million aggregate principal amount of 4.09% Senior Notes, Series A, due August 11, 2025, (vi) \$25.0 million aggregate principal amount of 4.18% Senior Notes, Series B, due August 11, 2026, (vii) \$25.0 million aggregate principal amount of 4.24% Senior Notes, Series C, due August 11, 2027, (viii) \$400.0 million aggregate principal amount of 4.30% Senior Notes, due March 15, 2027, and (ix) \$350.0 million aggregate principal amount of 3.95% Senior Notes, due January 15, 2028.

The note agreements covering the notes (other than the 2027 Senior Notes) contain covenants that are substantially similar to those contained in the Credit Agreement, including financial covenants that require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as other affirmative and negative covenants that may limit, among other things, our ability to incur additional debt, make distributions or investments, incur liens and sell, transfer or dispose of assets. The note agreements also include customary representations and warranties and customary events of default substantially similar to those contained in the Credit Agreement.

***ATM Program***

On August 5, 2016, the Trust and the Operating Partnership entered into separate At Market Issuance Sales Agreements (the “Sales Agreements”) with each of KeyBanc Capital Markets Inc., Credit Agricole Securities (USA) Inc., JMP Securities LLC, Raymond James & Associates, Inc., and Stifel Nicolaus & Company, Incorporated (the “Agents”), pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to \$300.0 million, through the Agents (the “ATM Program”). In accordance with the Sales Agreements, the Trust may offer and sell its common shares through any of the Agents, from time to time, by any method deemed to be an “at the market offering” as

## Table of Contents

defined in Rule 415 under the Securities Act of 1933, as amended, which includes sales made directly on the New York Stock Exchange or other existing trading market, or sales made to or through a market maker. With the Trust's express written consent, sales may also be made in negotiated transactions or any other method permitted by law.

During the quarterly period ended March 31, 2018, the Trust sold 311,786 common shares pursuant to the ATM Program, at a weighted average price of \$17.85 per share resulting in total net proceeds of approximately \$5.5 million.

As of April 30, 2018, the Trust has \$168.2 million remaining available under the ATM Program.

### ***Dividend Reinvestment and Share Purchase Plan***

In December 2014, we adopted a Dividend Reinvestment and Share Purchase Plan (the "DRIP"). Under the DRIP:

Existing shareholders may purchase additional common shares by reinvesting all or a portion of the dividends paid on their common shares and by making optional cash payments of not less than \$50 and up to a maximum of \$10,000 per month;

New investors may join the DRIP by making an initial investment of not less than \$1,000 and up to a maximum of \$10,000; and

Once enrolled in the DRIP, participants may authorize electronic deductions from their bank account for optional cash payments to purchase additional shares.

The DRIP is administered by our transfer agent, Computershare Trust Company, N.A. Our common shares sold under the DRIP will be newly issued or purchased in the open market, as further described in the DRIP. As of April 30, 2018, we have issued 57,931 common shares under the DRIP since its inception.

### ***Critical Accounting Policies***

Our consolidated financial statements included in Part I, Item 1 of this report are prepared in conformity with GAAP for interim financial information set forth in the Accounting Standards Codification ("ASC"), as published by the Financial Accounting Standards Board ("FASB"), which require us to make estimates and assumptions regarding future events that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base these estimates on our experience and assumptions we believe to be reasonable under the circumstances. However, if our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, we may have applied a different accounting treatment, resulting in a different presentation of our financial statements. We periodically reevaluate our estimates and assumptions, and in the event they prove to be different from actual results, we make adjustments in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Please refer to our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Commission on March 1, 2018, for further information regarding the critical accounting policies that affect our more significant estimates and judgments used in the preparation of our consolidated financial statements included in Part I, Item 1 of this report.

### ***REIT Qualification Requirements***

We are subject to a number of operational and organizational requirements necessary to qualify and maintain our qualification as a REIT. If we fail to qualify as a REIT or fail to remain qualified as a REIT in any taxable year, our income would be subject to federal income tax at regular corporate rates and potentially increased state and local taxes

and could incur substantial tax liabilities which could have an adverse impact upon our results of operations, liquidity and distributions to our shareholders.

**Off-Balance Sheet Arrangements**

As of March 31, 2018, we have no off-balance sheet debt.

Table of Contents**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

Our future income, cash flows and fair values relevant to financial instruments are dependent upon prevailing market interest rates. Market risk refers to the risk of loss from adverse changes in market prices and interest rates. We use certain derivative financial instruments to manage, or hedge, interest rate risks related to our borrowings. We do not use derivatives for trading or speculative purposes and only enter into contracts with major financial institutions based upon their credit rating and other factors. Our derivative instruments consist of five interest rate swaps. See Note 2 (Summary of Significant Accounting Policies) and Note 7 (Derivatives) to our consolidated financial statements included in Part I, Item 1 to this report for further detail on our interest rate swaps.

Interest risk amounts are our management's estimates and were determined by considering the effect of hypothetical interest rates on our consolidated financial instruments. These analyses do not consider the effect of any change in overall economic activity that could occur in that environment. Further, in the event of a change of that magnitude, we may take actions to further mitigate our exposure to the change. However, due to the uncertainty of the specific actions that would be taken and their possible effects, these analyses assume no changes in our financial structure.

***Fixed Interest Rate Debt***

As of March 31, 2018, our consolidated fixed interest rate debt totaled \$1.1 billion, which represented 70.1% of our total consolidated debt, excluding the impact of interest rate swaps. On July 7, 2016, we entered into a pay-fixed receive-variable rate swap for the full \$250.0 million borrowing amount of our term loan borrowings, fixing the LIBOR component of the borrowing rate to 1.07%, for an all-in fixed rate of 2.87%. Both the borrowing and pay-fixed receive-variable swap have a maturity date of June 10, 2023.

Assuming the effects of the interest rate swap agreement we entered into on July 7, 2016 relating to our unsecured debt, our fixed interest rate debt would represent 85.7% of our total consolidated debt. Interest rate fluctuations on our fixed interest rate debt will generally not affect our future earnings or cash flows unless such instruments mature or are otherwise terminated. However, interest rate changes could affect the fair value of our fixed interest rate debt.

As of March 31, 2018, the fair value and the carrying value of our consolidated fixed interest rate debt were approximately \$1.09 billion and \$1.12 billion, respectively. The fair value estimate of our fixed interest rate debt was estimated using a discounted cash flow analysis utilizing rates we would expect to pay for debt of a similar type and remaining maturity if the loans were originated on March 31, 2018. As we expect to hold our fixed interest rate debt instruments to maturity, based on the underlying structure of the debt instrument, and the amounts due under such instruments are limited to the outstanding principal balance and any accrued and unpaid interest, we do not expect that market fluctuations in interest rates, and the resulting change in fair value of our fixed interest rate debt instruments, would have a significant impact on our operating cash flows.

***Variable Interest Rate Debt***

As of March 31, 2018, our consolidated variable interest rate debt totaled \$478.9 million, which represented 29.9% of our total consolidated debt. Assuming the effects of the interest rate swap agreement we entered into on July 7, 2016 relating to our unsecured debt, our variable interest rate debt would represent 14.3% of our total consolidated debt. Interest rate changes on our variable rate debt could impact our future earnings and cash flows, but would not significantly affect the fair value of such debt. As of March 31, 2018, we were exposed to market risks related to fluctuations in interest rates on \$228.9 million of consolidated borrowings. Assuming no increase in the amount of our variable rate debt, if LIBOR were to change by 100 basis points, interest expense on our variable rate debt as of March 31, 2018 would change by approximately \$2.3 million annually.

*Derivative Instruments*

As of March 31, 2018, we had five outstanding interest rate swaps designated as a cash flow hedge of interest rate risk, with a total notional amount of \$250.0 million. See Note 7 (Derivatives) to our consolidated financial statements for further detail on our interest rate swaps. We are exposed to credit risk of the counterparty to our interest rate swap agreements in the event of non-performance under the terms of the agreements. If we were not able to replace these swaps in the event of non-performance by the counterparty, we would be subject to variability of the interest rate on the amount outstanding under our debt that is fixed through the use of the swaps.



Table of Contents

***Indebtedness***

As of March 31, 2018, we had total consolidated indebtedness of approximately \$1.6 billion. The weighted average interest rate on our consolidated indebtedness was 3.84% (based on the 30-day LIBOR rate as of March 31, 2018, of 1.80%). As of March 31, 2018, we had approximately \$228.9 million, or approximately 14.3%, of our outstanding long-term debt exposed to fluctuations in short-term interest rates. See Note 6 (Debt) to our consolidated financial statements included in Part I, Item 1 to this report for a summary of our indebtedness as of March 31, 2018.

**Item 4. Controls and Procedures**

**Physicians Realty Trust**

*Evaluation of Disclosure Controls and Procedures*

The Trust's management, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Trust's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this report. Based on such evaluation, the Trust's Chief Executive Officer and Chief Financial Officer concluded that as of March 31, 2018, the Trust's disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information it is required to disclose in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Commission, and that such information is accumulated and communicated to the Trust's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.

*Changes in Internal Control over Financial Reporting*

There have been no changes in the Trust's system of internal control over financial reporting during the quarter ended March 31, 2018 that have materially affected, or are reasonably likely to materially affect, the Trust's internal control over financial reporting.

*Limitations on Effectiveness of Controls and Procedures*

In designing and evaluating the disclosure controls and procedures and the Trust's internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and the Trust's internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

**Physicians Realty L.P.**

*Evaluation of Disclosure Controls and Procedures*

The Operating Partnership's management, with the participation of the Chief Executive Officer and Chief Financial Officer of the Operating Partnership's general partner, has evaluated the effectiveness of the Operating Partnership's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, the Chief Executive Officer and Chief Financial Officer of the Operating Partnership's general partner concluded that as of March 31, 2018, the Operating Partnership's

disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information it is required to disclose in reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Commission, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer of the Operating Partnership's general partner, as appropriate, to allow for timely decisions regarding required disclosure.

*Changes in Internal Control over Financial Reporting*

There have been no changes in the Operating Partnership's system of internal control over financial reporting during the quarter ended March 31, 2018, that have materially affected, or are reasonably likely to materially affect, the Operating Partnership's internal control over financial reporting.

Table of Contents

*Limitations on Effectiveness of Controls and Procedures*

In designing and evaluating the disclosure controls and procedures and the Operating Partnership's internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and the Operating Partnership's internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

**PART II. Other Information**

**Item 1. Legal Proceedings**

From time to time, we are party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. We are not currently a party, as plaintiff or defendant, to any legal proceedings which, individually or in the aggregate, would be expected to have a material effect on our business, financial condition or results of operations if determined adversely to us.

**Item 1A. Risk Factors**

*The following risk factors and other information included in this report should be carefully considered. The risks and uncertainties described below are not the only ones we face. You should also carefully consider the risk factors described in Part I, Item 1A (Risk Factors) of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Commission on March 1, 2018 (the "Annual Report"). Our business, financial condition and operating results can be materially adversely affected by a number of factors, whether currently known or unknown, including, but not limited to, those described below, any one or more of which could, directly or indirectly, cause our actual results of operations and financial condition to vary materially from past, or from anticipated future, results of operations and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, results of operations and common stock price. In such case, the market value of our securities could be detrimentally affected, and investors may lose part or all of the value of their investment.*

*The following discussion of risk factors contains forward-looking statements. These risk factors and the risk factors described in Part I, Item 1A (Risk Factors) of the Annual Report may be important to understanding any statement in this report or elsewhere. The following information should be read in conjunction with our consolidated and combined financial statements, and related notes, included in Part I, Item 1, "Financial Statements" and Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" of this report.*

*Because of the following factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods. You should carefully consider the risks and uncertainties described below as well as the risk factors described in Part I, Item 1A (Risk Factors) of the Annual Report.*

**Risks Related To Our Business**

*Economic and other conditions that negatively affect geographic areas in which we conduct business, and in particular Texas, and other areas to which a greater percentage of our revenue is attributed could materially adversely affect our business, results of operations, and financial condition.*

Our operating results depend upon our ability to maintain and increase occupancy levels and rental rates at our properties. Adverse economic or other conditions in the geographic markets in which we operate, including periods of economic slowdown or recession, industry slowdowns, periods of deflation, relocation of businesses, changing demographics, earthquakes and other natural disasters, fires, terrorist acts, civil disturbances or acts of war, and other man-made disasters which may result in uninsured or underinsured losses, and changes in tax, real estate, zoning, and other laws and regulations, may lower our occupancy levels and limit our ability to increase rents or require us to offer rental concessions.

For the quarter ended March 31, 2018, approximately 1.9 million feet of our gross leasable area and \$47.1 million of our total annualized base rent, exclusive of our held for sale assets, was derived from properties located in Texas (14.2% of our gross leasable area and 16.7% of our total annualized base rent). As a result of these geographic concentrations, we are particularly exposed to downturns in the Texas economy or other changes in local real estate market conditions. Any material

Table of Contents

change in the current payment programs or regulatory, economic, environmental, or competitive conditions in Texas could have a disproportionate effect on our overall business results. In the event of negative economic or other changes in any of the markets in which we conduct business, our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares may be adversely affected.

***We may in the future make investments in joint ventures, which could be adversely affected by our lack of decision-making authority, our reliance upon our joint venture partners' financial condition, any disputes that may arise between us and our joint venture partners and our exposure to potential losses from the actions of our joint venture partners.***

We may in the future make co-investments with third parties through partnerships, joint ventures or other entities, acquiring noncontrolling interests in or sharing responsibility for the management of the affairs of a property, partnership, joint venture or other entity. Joint ventures generally involve risks not present with respect to our wholly-owned properties, including the following:

• our joint venture partners may make management, financial and operating decisions with which we disagree or that are not in our best interest;

• we may be prevented from taking actions that are opposed by our joint venture partners;

• our ability to transfer our interest in a joint venture to a third party may be restricted;

• our joint venture partners might become bankrupt or fail to fund their share of required capital contributions which may delay construction or development of a healthcare related facility or increase our financial commitment to the joint venture;

• our joint venture partners may have business interests or goals with respect to the healthcare related facility that conflict with our business interests and goals which could increase the likelihood of disputes regarding the ownership, management or disposition of the healthcare related facility or the joint venture may compete with us for property acquisitions;

• disputes may develop with our joint venture partners over decisions affecting the healthcare related facility or the joint venture which may result in litigation or arbitration that would increase our expenses and distract our officers and/or trustees from focusing their time and effort on our business and possibly disrupt the daily operations of the healthcare related facility; and

• we may suffer losses as a result of the actions of our joint venture partners with respect to our joint venture investments.

Joint venture investments involve risks that may not be present with other methods of ownership. In addition to those risks identified above, our partners might at any time have economic or other business interests or goals that are or become inconsistent with our interests or goals; that we could become engaged in a dispute with our partners, which could require us to expend additional resources to resolve such disputes and could have an adverse impact on the operations and profitability of the joint venture; and that our partners may be in a position to take action or withhold consent contrary to our instructions or requests. In addition, our ability to transfer our interest in a joint venture to a third party may be restricted. In the future, in certain instances, we or our partners may have the right to trigger a buy-sell arrangement, which could cause us to sell our interest, or acquire our partners' interest, at a time when we otherwise would not have initiated such a transaction. Our ability to acquire our partners' interest may be limited if we

do not have sufficient cash, available borrowing capacity or other capital resources. In such event, we may be forced to sell our interest in the joint venture when we would otherwise prefer to retain it. Joint ventures may require us to share decision-making authority with our partners, which could limit our ability to control the properties in the joint ventures. Even when we have a controlling interest, certain major decisions may require partner approval, such as the sale, acquisition or financing of a property.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

**Recent Sales of Unregistered Securities**

From time to time the Operating Partnership issues OP Units to the Trust, as required by the Partnership Agreement, to reflect additional issuances of common shares by the Trust and to preserve equitable ownership ratios.

Table of Contents**Purchases of Equity Securities by the Issuer and Affiliated Purchasers**

The following table sets forth information relating to repurchases of our common shares of beneficial interest and OP Units during the three months ended March 31, 2018:

**ISSUER PURCHASES OF EQUITY SECURITIES**

Period	(a) Total Number of Shares (or Units) Purchased	(b) Average Price Paid per Share (or Unit)	(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
January 1, 2018 - January 31, 2018	7,040	(1)\$ 17.79	N/A	N/A
February 1, 2018 - February 28, 2018	—	—	N/A	N/A
March 1, 2018 - March 31, 2018	—	—	N/A	N/A
Total	7,040	\$ 17.79	—	—

(1) Represents OP Units redeemed by holders in exchange for common shares of the Trust.

Table of Contents

**Item 6. Exhibits**

Exhibit No.	Description
<u>10.1</u>	(1) <u>Employment Agreement dated as of February 28, 2018, between the Company and John T. Thomas**</u>
<u>10.2</u>	(1) <u>Employment Agreement dated as of February 28, 2018, between the Company and Jeffrey N. Theiler**</u>
<u>10.3</u>	(1) <u>Employment Agreement dated as of February 28, 2018, between the Company and D. Deeni Taylor**</u>
<u>10.4</u>	(1) <u>Employment Agreement dated as of February 28, 2018, between the Company and Bradley D. Page**</u>
<u>10.5</u>	(1) <u>Employment Agreement dated as of February 28, 2018, between the Company and John W. Lucey**</u>
<u>10.6</u>	(1) <u>Employment Agreement dated as of February 28, 2018, between the Company and Daniel M. Klein**</u>
<u>10.7</u>	(1) <u>Employment Agreement dated as of February 28, 2018, between the Company and Mark D. Theine**</u>
<u>10.8</u>	(1) <u>Form of Restricted Share Unit Award Agreement (Performance Units)**</u>
<u>31.1</u>	<u>Certification of John T. Thomas, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Physicians Realty Trust*</u>
<u>31.2</u>	<u>Certification of Jeffrey N. Theiler, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Physicians Realty Trust*</u>
<u>31.3</u>	<u>Certification of John T. Thomas, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Physicians Realty L.P.*</u>
<u>31.4</u>	<u>Certification of Jeffrey N. Theiler, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Physicians Realty L.P.*</u>
<u>32.1</u>	<u>Certification of John T. Thomas and Jeffrey N. Theiler, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) for Physicians Realty Trust*</u>
<u>32.2</u>	<u>Certification of John T. Thomas and Jeffrey N. Theiler, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) for Physicians Realty L.P.*</u>
101.INS	XBRL Instance Document (+)
101.SCH	XBRL Extension Schema Document (+)
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document (+)
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document (+)
101.LAB	XBRL Taxonomy Extension Label Linkbase Document (+)
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document (+)

\* Filed herewith

\*\* Indicates a management contract or compensatory plan or arrangement.

(1) Incorporated by reference to the Registrant's Current Report on Form 8-K filed with the SEC on February 28, 2018 (File No. 001-36007).

(+) Users of this data are advised pursuant to Rule 406T of Regulation S-T that this interactive data file is deemed not filed or part of a registration statement for purposes of Section 11 or 12 of the Securities Act, is deemed not filed for purposes of Section 18 of the Exchange Act, and otherwise is not subject to liability under these sections.



Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**PHYSICIANS REALTY TRUST**

Date: May 4, 2018 /s/ John T. Thomas

John T. Thomas  
Chief Executive Officer and President  
(Principal Executive Officer)

Date: May 4, 2018 /s/ Jeffrey N. Theiler

Jeffrey N. Theiler  
Executive Vice President and Chief Financial Officer  
(Principal Financial Officer)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**PHYSICIANS REALTY L.P.**

**By: Physicians Realty Trust, its general partner**

Date: May 4, 2018 /s/ John T. Thomas

John T. Thomas  
Chief Executive Officer and President  
(Principal Executive Officer)

Date: May 4, 2018 /s/ Jeffrey N. Theiler

Jeffrey N. Theiler  
Executive Vice President and Chief Financial Officer  
(Principal Financial Officer)